+

WO2011018665A1 - Système complexant - Google Patents

Système complexant Download PDF

Info

Publication number
WO2011018665A1
WO2011018665A1 PCT/GB2010/051336 GB2010051336W WO2011018665A1 WO 2011018665 A1 WO2011018665 A1 WO 2011018665A1 GB 2010051336 W GB2010051336 W GB 2010051336W WO 2011018665 A1 WO2011018665 A1 WO 2011018665A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
helix
helices
derived
snare
Prior art date
Application number
PCT/GB2010/051336
Other languages
English (en)
Inventor
Bazbek Davletov
Frederic Darios
Enrico Ferrari
Mikhail Soloviev
Original Assignee
Medical Research Council
Royal Holloway And Bedford New College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0914121A external-priority patent/GB0914121D0/en
Application filed by Medical Research Council, Royal Holloway And Bedford New College filed Critical Medical Research Council
Priority to JP2012524293A priority Critical patent/JP2013501771A/ja
Priority to AU2010283595A priority patent/AU2010283595A1/en
Priority to EP10747066A priority patent/EP2464662A1/fr
Priority to CA2770357A priority patent/CA2770357A1/fr
Priority to CN2010800444464A priority patent/CN102625812A/zh
Publication of WO2011018665A1 publication Critical patent/WO2011018665A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Definitions

  • the present invention relates to a complexing system for forming a molecular scaffold which is based on the SNARE complex.
  • vesicles are merged with a membrane in a process known as vesicle fusion.
  • vesicle fusion In eukaryotic cells, vesicles are merged with a membrane in a process known as vesicle fusion.
  • vesicle fusion can be merged with the cell plasma membrane or other cell compartments such as endosomes or lysosomes.
  • the most studied form of vesicle fusion is the docking of synaptic vesicles with the pre-synaptic membrane in neuronal cells to release neurotransmitters to cause propagation of a nerve impulse in the post-synaptic neuron.
  • SNARE proteins are a large protein superfamily consisting of more than 60 members in yeast and mammalian cells. SNAREs are small, abundant and mostly membrane-bound proteins. Although they vary considerably in structure and size, they all share segments in their cytosolic domains called SNARE motifs that are capable of assembly into a tight, four -helix bundle called a SNARE complex. It is thought that SNARE motifs are about 60-70 amino acids in length (Jahn R and Scheller RH), although this is not well defined.
  • SNARE complexes are sometimes composed of three proteins: syntaxin and SNAP-25, which are resident in the cell membrane; and synaptobrevin (also referred to as vesicle-associated membrane protein or VAMP), which is anchored in the vesicular membrane.
  • syntaxin and SNAP-25 which are resident in the cell membrane
  • synaptobrevin also referred to as vesicle-associated membrane protein or VAMP
  • syntaxin and synaptobrevin are anchored in their respective membranes by their C-terminal domains, whereas SNAP-25 is tethered to the plasma membrane via several cysteine-linked palmitoyl chains.
  • the core SNARE complex is a four- ⁇ -helix bundle in which one ⁇ -helix is contributed by syntaxin, one ⁇ -helix is contributed by synaptobrevin and two ⁇ -helices are contributed by SNAP-25. This SNARE complex has been found to be very stable.
  • Figure 1 A schematic representation of the molecular machinery involved in vesicle fusion is shown in Figure 1. Summary of Invention
  • the inventors have found that the SNARE complex and the formation of it can be used for various applications.
  • the basis of the invention is a complexing system comprising:
  • polypeptide helix derived from synaptobrevin or a homolog thereof
  • the invention also relates to a method of producing a stable SNARE complex using the above complexing system and use of the above complexing system and resulting stable SNARE complex.
  • a complexing system for forming a molecular scaffold comprising:
  • polypeptide helix derived from synaptobrevin or a homolog thereof
  • the present invention allows the controlled assembly of a stable complex formed of distinct functional units.
  • the advantage of having a stable complex is that it can be used in relatively harsh conditions without the risk of the complex dissociating. This means that the helix or helices to which the one or more cargo moiety is/are attached will remain part of the complex, ensuring that the one or more cargo moiety does not dissociate from the rest of the complex.
  • the complexing system is based on the formation of a stable SNARE complex. Therefore, the four polypeptide helices of the present invention can, to a certain degree, have any sequence as long as they can form a stable SNARE complex.
  • the SNARE complex is formed from the following proteins: SNAP-25; syntaxin; and synaptobrevin. These proteins, as well as other SNARE proteins, contain SNARE motifs or SNARE domains which are the portions of the proteins which are involved in forming the SNARE complex. These SNARE domains or motifs are helices which pack together to form the SNARE complex. Generally, only a portion of the SNARE proteins is involved in SNARE complex formation; not the entire SNARE protein. For example, syntaxin has a C-terminal transmembrane domain, a SNARE domain and an N-terminal regulatory domain, also known as the head domain. Obviously, only the SNARE domain is involved in forming the SNARE complex.
  • SNARE motif and SNARE domain are well known to those skilled in the art. Further, the SNARE motifs and SNARE domains of the various different SNARE proteins are also well known to a skilled person (Jahn R and Scheller RH (2006); Sieber et al. (2006); Besteiro (2006)).
  • the four polypeptide helices of the present invention are based on the SNARE domains or motifs of the SNARE proteins that form the SNARE complex, i.e. a SNAP protein; syntaxin; and synaptobrevin or a homolog thereof.
  • the complexing system comprises: two polypeptide helices derived from the SNARE motif of a SNAP protein; one polypeptide helix derived from the SNARE motif of syntaxin; and one polypeptide helix derived from the SNARE motif of synaptobrevin or a homolog thereof, wherein the four polypeptide helices can form a stable SNARE complex. It may not be necessary for a helix of the invention to be the same length as the SNARE motif or domain from a SNARE protein. It may be shorter in length as long as it can still form a stable SNARE complex when complexed with the other helices of the invention.
  • the SNAP protein from which the two polypeptide helices are derived can be any SNAP protein which can form part of a SNARE complex.
  • the skilled person is aware of the various SNAP proteins which can form part of a
  • the SNAP protein may be SNAP-25A, SNAP-25B, SNAP-23 (also known as syndet), or SNAP-29.
  • the SNAP protein is not ⁇ -SNAP.
  • the SNAP protein is SNAP-25, i.e.
  • SNAP-25A or SNAP-25B SNAP proteins contain two SNARE motifs. Therefore, the two polypeptide helices may be derived from the two SNARE motifs in a particular SNAP protein. Alternatively, the two polypeptide helices may be derived from different SNAP proteins. Preferably, they are derived from the same SNAP protein.
  • syntaxin protein from which the polypeptide helix is derived can be any syntaxin protein which can form part of a SNARE complex.
  • the syntaxin protein may be selected from syntaxin IA, syntaxin IB, syntaxin 2 (also known as epimorphin), syntaxin 3 and syntaxin 4, syntaxin 5, syntaxin 6, syntaxin 7, syntaxin 8, syntaxin 10, syntaxin 11, syntaxin 13, syntaxin 17 or syntaxin 18.
  • the syntaxin protein is syntaxin IA or 3.
  • the synaptobrevin protein or homolog thereof from which the polypeptide helix is derived can be any synaptobrevin protein or homolog which can form part of a SNARE complex.
  • Synaptobrevin is a member of the vesicle-associated membrane protein (VAMP) family.
  • VAMP vesicle-associated membrane protein
  • Other VAMP proteins are known to be able to form SNARE complexes and, therefore, may be suitable for providing the basis upon which a polypeptide helix can be derived.
  • homologs of synaptobrevin are VAMP proteins which can form part of a SNARE complex. Such VAMP proteins are well known to those skilled in the art.
  • synaptobrevin protein or homolog thereof may be selected from synaptobrevin 1, synaptobrevin 2, synaptobrevin 3 (also known as cellubrevin) and synaptobrevin 7 (also known as TI-VAMP).
  • the polypeptide helix is derived from a synaptobrevin protein.
  • the synaptobrevin protein is synaptobrevin 1, 2 or 3.
  • the organism from which the SNARE proteins originate can be any suitable organism in which SNARE complexes are utilised.
  • the proteins may originate from: mammals, such as humans, primates, and rodents; fish; and invertebrates, such as flies.
  • the SNARE proteins may be derived from yeast (Rossi G et al. (1997)).
  • the organism from which the SNARE proteins originate may depend on the application of the complexing system. For example, for medical applications, the SNARE proteins preferably originate from humans.
  • the four polypeptide helices of the invention are derived from the SNARE proteins which form the SNARE complex.
  • the helices of the SNARE motif or domain of the SNARE proteins which form the SNARE complex are generally about 60-70 amino acids in length.
  • the four polypeptide helices of the invention are derived from the SNARE motif or SNARE domain of the SNARE proteins.
  • the term "derived from” means that the sequence of the polypeptide helix is substantially the same as the sequence of the SNARE domain/motif or a portion thereof so that it is capable of forming a stable SNARE complex.
  • the sequence of the polypeptide helix should have at least about 80% sequence identity with the sequence of the selected SNARE domain/motif or the portion thereof.
  • sequence identity should be at least about 85%, and even more preferably at least about 90%. In one embodiment, the sequence identity may be at least about 95%, at least about 98% or even 100%. However, in some embodiments, it may be preferable for the sequence of the polypeptide helix to differ from the sequence of the selected SNARE domain/motif or the portion thereof. This may be beneficial in terms of expression of the protein, purification of the protein or down-stream applications. For example, and without limitation, this may include the addition of histidine residues at either end of the sequence to enable purification, or incorporation of additional lysine or cysteine residues for functional attachment of the peptides to surfaces or cargoes.
  • the two SNAP derived helices may comprise a sequence selected from SEQ ID NOs. 1, 2, 5, 6, 24, 41, 48, 49, 50, 51, 64 and 65.
  • the syntaxin derived helix may comprise a sequence selected from SEQ ID NOs. 3, 7, 9, 25, 32, 33, 34, 35, 36, 37, 38, 46, 47, 60, 61, 62 and 66.
  • the helix derived from synaptobrevin or a homolog thereof may comprise a sequence selected from SEQ ID NOs. 4, 8, 27, 28, 29, 30, 31, 42, 43, 44, 45, 52, 53, 67, 68 and 69. Further, the helices derived from the SNARE proteins may consist of the above sequences.
  • Adverse conditions are those which generally cause dissociation of protein complexes and protein-protein interactions. Such conditions will be apparent to a skilled person. For example, such adverse conditions may be exposing the complex to a strong surfactant or a disrupting detergent.
  • a SNARE complex can be tested to determine whether it is stable by using SDS-PAGE which is performed in the presence of denaturing SDS concentrations (> 0.02 %). If the complex is dissociated by the SDS in the gel so that it separates into its component parts, the SNARE complex may not be stable.
  • the SNARE complex can be considered to be stable if it does not dissociate using SDS.
  • the SNARE complex is stable when using a gel sample buffer for SDS-PAGE containing about 2% SDS. More preferably, the SNARE complex is stable when using a gel for SDS-PAGE containing about 0.1% SDS. This can be done using a gel for the SDS-PAGE which contains about 0.1% SDS.
  • the stability of the SNARE complex can be verified by bead pull-down.
  • the SNARE complex can be considered to be stable if one component of the complexing system will bring down all interacting partners in a stoichiometric manner. Bead pull-down is well-known to a skilled person (Rickman C. et al. (2004)).
  • Another method of determining whether a SNARE complex is stable is to determine the dissociation constant of the complex. This is the dissociation constant for one helix dissociating from the complex.
  • a stable SNARE complex should have a dissociation constant of less than 10 "7 M.
  • the stable SNARE complex may have a dissociation constant of less than 10 "8 , 10 "9 , 10 "10 , 10 "11 , 10 "12 , 10 "13 , 10 "14 , or 10 "15 M.
  • the dissociation constant may be 10 "7 M to 10 "11 M or 10 "7 M to 10 "10 M.
  • the dissociation constant may be comparable to antibody dissociation constants (6-10 xlO "8 M).
  • SNARE complex formation can also be assessed by binding to complexin which binds to the fully formed SNARE complex (Hu et al. (2002)).
  • the polypeptide helices of the present invention are at least about 25 amino acids in length. SNARE complexes using such helices can form in solution. However, they may not be SDS resistant. Preferably, the polypeptide helices of the present invention are at least about 30 or about 35 amino acids in length.. More preferably, the polypeptide helices of the present invention are at least about 40 amino acids in length. SNARE complexes formed using such helices are generally SDS resistant. Alternatively, the polypeptide helices may be at least about 45 amino acids in length. In one embodiment, at least one of the polypeptide helices is less than 50 amino acids in length.
  • the advantage of this is that it is much easier to artificially manufacture polypeptides which are less than 50 amino acids in length.
  • the polypeptide helices which are less than 50 amino acids can be any of the polypeptide helices.
  • at least two of the polypeptide helices are less than 50 amino acids in length.
  • they are the polypeptide helices derived from syntaxin and synaptobrevin or a homolog thereof.
  • three or four of the polypeptide helices may be less than 50 amino acids in length. In such embodiments, any combination of helices can be less than 50 amino acids in length.
  • two of the polypeptide helices are less than 50 amino acids in length, preferably it is the helix derived from syntaxin and the helix derived from synaptobrevin or a homolog thereof which are less than 50 amino acids in length.
  • the four polypeptide helices of the invention may be about the same length or may be different in length. For example, in one embodiment they may all be about 45 amino acids in length. Alternatively, the polypeptide helices may be different lengths.
  • the polypeptide derived from syntaxin and/or the polypeptide derived from synaptobrevin or a homolog thereof may further comprise a membrane attachment sequence to allow immobilisation of the SNARE complex to membranes or lipid bilayers.
  • membrane attachment sequences are well known to those skilled in the art.
  • the native sequences of syntaxin and synaptobrevin contain transmembrane portions to allow attachment of the protein to vesicle and cellular membranes (Kasai and Akagawa (2001) and Laage et al. (2000)).
  • the polypeptide helix derived from syntaxin may further comprise a membrane attachment sequence derived from the syntaxin transmembrane domain for immobilising the polypeptide helix to a membrane or lipid bilayer.
  • the polypeptide helix derived from synaptobrevin or a homolog thereof may further comprise a membrane attachment sequence derived from the transmembrane domain of synaptobrevin or a homolog thereof for immobilising the polypeptide helix to a membrane or lipid bilayer.
  • a stable SNARE complex is one which does not dissociate under adverse conditions which generally cause dissociation of protein complexes and protein-protein interactions. This may be measured, for example, using SDS- PAGE, bead pull-down, surface plasmon resonance of immobilised protein, the dissociation constant or complexin binding. This is discussed in more detail above.
  • the one or more cargo moiety may be any moiety which a skilled person might want to attach to the polypeptide helices.
  • the one or more cargo moiety is preferably attached to the end of the helices in the complexing system.
  • the cargo moiety may be selected from a small molecule, a polymer containing a small molecule, a polypeptide, a protein, a nucleic acid or derivative, and a particle or nanoparticle.
  • the cargo moiety may be:
  • a small molecule or a polymer containing a small molecule such as:
  • an affinity tag e.g. biotin
  • a therapeutic e.g. a toxin or a drug
  • a reactive group for further/downstream cross-linking, polymerisation and further derivatisation e.g. an amino group, carboxyl group, sulfhydryl group, guanidine group, phenolic group, thioether group, imidazol group, indol group, etc.;
  • a spontaneously reactive group suitable for further modification e.g. a maleimide or derivative for cross-linking to SH groups, or any other chemistry suitable for cross-linking;
  • molecule for direct attachment to surfaces e.g. an SH- containing molecule for attachment to metal surfaces
  • an imaging reagent e.g. a fluorescent or absorbent moiety for UV, VIS, IR, Raman, NMR, MRI, PET, X-ray or other imaging;
  • a biologically relevant ligand e.g. for receptor binding/targeting
  • a biologically relevant substrate e.g. a phosphorylation or other PTM site
  • a biologically relevant molecule e.g. a lipid or carbohydrate
  • a protective group or molecule e.g. PEG
  • polypeptide or protein such as:
  • polypeptide or protein containing a functional site e.g. a protease digestion site
  • a targeting functional peptide e.g. for different organelle targeting, nuclear targeting (for transfection), intracellular targeting (for drug delivery), etc.;
  • peptide affinity tag e.g. Flag, Myc, VSV, HA, 6xHis, 8xhis, poly- His, etc.;
  • polypeptide or protein capable of forming a protein-protein interaction e.g. PDZ, SH2/3;
  • an enzyme e.g. for research, diagnostics (the complexing system can be used to immobilise enzymes for some applications) and therapeutic applications, for nucleic acid synthesis or amplification including promoters, polymerases, restriction endonucleases, or other modifying enzymes;
  • nucleic acid or derivative such as:
  • RNA, or PNA for detection, immobilisation, hybridisation, synthesis priming, synthesis and amplification, labelling, signal detection and signal amplification, transcription and translation; and 4. a particle or nanoparticle such as:
  • a metallic particle or nanoparticle e.g. gold or silver for staining or labelling
  • a semiconductor particle or nanoparticle e.g. quantum dots for labelling and detection
  • a polymer micro or nanoparticle e.g. resins, gels, etc.
  • a plurality of cargo moieties can be attached to the ends of the polypeptide helices.
  • the number of cargo moieties that can be attached to the ends of polypeptide helices will depend on how many free ends are present on the helices. For example, where the complexing system comprises four separate polypeptide helices, the helices will have eight free ends (one at each end of each helix). Therefore, it is possible to attach a cargo moiety to each of the eight free ends. This means that 1, 2, 3, 4, 5, 6, 7 or 8 cargo moieties could be attached to the free ends of the helices.
  • the number of free ends is reduced. This will reduce the number of cargo moieties that can be attached to the ends of the helices.
  • two or more cargo moieties can be attached at an end of a helix.
  • a first cargo moiety is attached to the end of a first helix and a second cargo moiety is attached to the end of a second helix.
  • the first and second cargo moieties should not be attached together on the same helix or helix containing component. They should be attached to separate helices or helix containing components.
  • the two cargo moieties may be attached to two single independent helices.
  • the first cargo moiety may be attached to the synaptobrevin/syntaxin fusion protein and the second cargo moiety may be attached to one of the helices derived from a SNAP protein.
  • the first cargo moiety should be attached to the first helix containing component and the second cargo moiety should be attached to the second helix containing component.
  • the first cargo moiety is an enzymatic or imaging moiety.
  • the second cargo moiety is a ligand for targeting the complexing system to a particular target, for example, a particular type of cell or a particular receptor.
  • the first cargo moiety is an enzymatic or imaging moiety and the second cargo moiety is a ligand for targeting the complexing system to a particular target, for example, a particular type of cells or a particular receptor.
  • the enzymatic or imaging agent may be any suitable agent.
  • the imaging agent can be any agent which can be attached to a helix and which allows the position of the helix to be imaged, for example, a GFP fluorescent tag, fluorescently labelled peptides, and MRI contrast agents.
  • the enzymatic agent can be any enzyme or functional portion thereof.
  • the enzymatic or imaging agent is an enzymatic agent.
  • the enzymatic agent comprises the light chain of a botulinum toxin or a functional portion thereof.
  • the function of the light chain of a botulinum toxin is as an endopeptidase. Therefore, a functional portion of the light chain of a botulinum toxin is a portion which retains the endopeptidase activity.
  • the enzymatic agent comprises the light chain of a botulinum toxin.
  • the light chain of the botulinum toxin can be from any botulinum toxin.
  • There are seven different types of botulinum toxin which are A, B, C, D, E, F and G.
  • the light chain is from botulinum toxin A or E and, more preferably, the light chain is from botulinum toxin A.
  • the enzymatic agent comprises the light chain of a botulinum toxin or a functional portion thereof and the translocation portion of the heavy chain of a botulinum toxin.
  • the translocation portion of the heavy chain of the botulinum toxin allows the light chain associated with it to be released from a vesicle into the cytosol of a cell.
  • a skilled person would readily understand what is meant by the term 'the translocation portion of the heavy chain of the botulinum toxin', which may also be referred to as the translocation domain.
  • the translocation portion of the heavy chain of the botulinum toxin can be from any botulinum toxin.
  • the translocation portion is from botulinum toxin A or E and, more preferably, from botulinum toxin A.
  • the light chain or functional portion thereof and the translocation portion can be from the same or different botulinum toxins.
  • the light chain or functional portion thereof and the translocation portion are from the same botulinum toxin.
  • the light chain or functional portion thereof and translocation portion may be joined in any suitable way. Preferably, they are joined via a disulphide bond as in a naturally occurring botulinum toxin.
  • the light chain of a botulinum toxin or a functional portion thereof and the translocation portion of the heavy chain of a botulinum toxin are joined by a peptide bond between the amino acid chains, preferably, there is a nicking site in the amino acid sequence between the light chain of a botulinum toxin or a functional portion thereof and the translocation portion of the heavy chain of a botulinum toxin which is recognised by a protease to cause cleavage of the amino acid sequence between the two parts.
  • the nicking site is a thrombin site which can be cleaved by thrombin.
  • the light chain of a botulinum toxin or a functional portion thereof and the translocation portion of the heavy chain of a botulinum toxin may be attached to one of the polypeptide helices derived from a SNAP protein.
  • the sequence of the light chain of the botulinum toxin may comprise the sequence as shown in SEQ ID NO. 70.
  • sequence of the translocation portion of the heavy chain of the botulinum toxin may comprise the sequence as shown in SEQ ID NO. 71.
  • the cargo moiety when it is a ligand, it can be any suitable ligand for targeting the complexing system to a particular target, for example, a particular type of cell or a particular receptor.
  • ligands are well known to those skilled in the art.
  • the ligand may be capable of binding to a cell surface receptor.
  • Such ligands could include neuropeptides such as substance P, neuropeptide Y and VIP, growth factors such as NGF and BDNF, and hormones such as pituitary hormones (e.g. ACTH, TSH, PRL, GH, endorphins, FSH, LH, oxytocin, ADH and AVP), GNRH and CGRP.
  • the ligand is a somatostatin peptide or a functional portion thereof which allows the somatostatin peptide to bind to a somatostatin receptor.
  • the ligand may be a substance P peptide or a functional portion thereof which allows the substance P peptide to bind to a neurokinin receptor or the ligand may be an AVP peptide or a functional portion thereof which allows the AVP peptide to bind to an AVP receptor.
  • the ligand may be the receptor binding portion of the heavy chain of a botulinum toxin.
  • the receptor binding portion of the heavy chain of a botulinum toxin is responsible for recognition of neuronal gangliosides and binds to synaptic vesicle receptor, SV2C, allowing the toxin to be endocytosed into the cell.
  • the term 'receptor binding portion of the heavy chain of a botulinum toxin' would be readily understood by a skilled person and may also be referred to as the receptor binding domain.
  • the receptor binding portion can be from any botulinum toxin.
  • the receptor binding portion is from botulinum toxin A or E and, more preferably, the receptor binding portion is from botulinum toxin A.
  • the receptor binding portion of the heavy chain of a botulinum toxin is attached to the polypeptide helix derived from synaptobrevin or a homolog thereof.
  • the sequence of the receptor binding portion of the heavy chain of the botulinum toxin may comprise the sequence as shown in SEQ ID NO. 72.
  • the present invention also provides the above complexes for use in therapy and/or diagnosis.
  • the exact nature of the therapy and/or diagnosis will depend on the identity of the ligand and enzymatic agent/imaging agent.
  • the first cargo moiety is an enzymatic agent comprising the light chain of a botulinum toxin or a functional portion thereof and the translocation portion of the heavy chain of a botulinum toxin
  • the second cargo moiety is a ligand which is the receptor binding portion of the heavy chain of a botulinum toxin.
  • the first cargo moiety is an enzymatic agent comprising the light chain of a botulinum toxin or a functional portion thereof and the translocation portion of the heavy chain of a botulinum toxin
  • the second cargo moiety is a ligand which is a somatostatin peptide or a functional portion thereof.
  • the one or more cargo moiety may be joined directly to the end of the helix or may be attached via a linker.
  • Suitable linkers are well known to those skilled in the art. For example, this may be done chemically or, if the cargo moiety is a protein or polypeptide, recombinantly.
  • the cargo moiety may be attached via a linker. Such linkers are well known to those skilled in the art.
  • the four polypeptide helices may be four separate helices which are not joined together in any way until they form a SNARE complex.
  • two of the helices may be joined together so that the complexing system comprises three separate components (referred to hereinafter as a three component system).
  • the two helices may be joined together in any suitable way as long as the two helices can assemble into the same stable SNARE complex.
  • the two helices may be joined together by recombinant means or chemically coupled.
  • the two helices may be joined together via a linker.
  • the term "join” means the linear linking of helices (this is in contrast to binding of helices which happens in parallel orientation akin to 'zippering'). Joining two helices together helps to simplify the complexing system. Any two helices may be joined together.
  • the two polypeptide helices derived from a SNAP protein are joined together. The advantage of this is that a full length SNAP protein can be used which comprises two polypeptide SNARE helices in the protein, for example, a full length SNAP-25 protein.
  • the polypeptide helix derived from syntaxin may be joined to the polypeptide helix derived from synaptobrevin or a homolog thereof.
  • two of the helices are joined together whilst the other two helices are also joined together.
  • the two sets of helices may be joined together in any suitable way as long as they can still form a stable SNARE complex.
  • the two sets of helices may be joined together by recombinant means or chemically coupled.
  • One or both sets of helices may be joined together via a linker. Any combination of helices can be joined together to form the two sets of two helices.
  • the two polypeptide helices which are derived from a SNAP protein are joined together and the helices derived from syntaxin and synaptobrevin or a homolog thereof are joined together.
  • three of the helices can be joined together.
  • the three helices may be joined together in any suitable way as long as they can still form a stable SNARE complex with the fourth helix.
  • the three helices may be joined together by recombinant means or chemically coupled.
  • the three helices may be joined together with a linker between two of the helices or between all three helices. Any three helices can be joined together.
  • the two polypeptide helices which are derived from a SNAP protein are joined together along with a third helix, i.e. the helix derived from syntaxin or the helix derived from synaptobrevin or a homolog thereof.
  • the two polypeptide helices which are derived from a SNAP protein are joined together along with the polypeptide helix derived from synaptobrevin or a homolog thereof.
  • the two polypeptide helices which are derived from a SNAP protein are joined together along with the polypeptide helix derived from syntaxin.
  • the cargo moiety is attached to the fourth single helix, for example, to syntaxin when the two polypeptide helices which are derived from a SNAP protein are joined together along with the polypeptide helix derived from synaptobrevin or a homolog thereof.
  • a FLAG epitope can be attached to a protein of interest and recognised by its cognate antibody much as a syntaxin-derived tag can be added to a protein of interest and recognised by a tri-helical construct of SNAP25 and synaptobrevin helices.
  • the affinity of the interaction between the tri-helical SNARE construct and the lone SNARE tag may be such that is allows for immobilisation of the protein, or may be reversible for other applications. This is advantageous because the tri- helical construct is cheaper to produce than an antibody.
  • the head domain of syntaxin 3 protects its SNARE motif from SNARE assembly but certain detergents and/or lipids can 'open' syntaxin for SNARE assembly (Darios and Davletov (2006); Rickman and Davletov (2005)). Therefore, in one embodiment in which the syntaxin derived helix has a syntaxin head domain attached to it, the system further comprises a detergent, preferably a mild detergent, such as octylglucopyranoside to open the syntaxin molecule to allow the formation of a stable SNARE complex. This allows the syntaxin SNARE motif to be controlled and, therefore, allows regulation of the formation of a SNARE complex.
  • a detergent preferably a mild detergent, such as octylglucopyranoside to open the syntaxin molecule to allow the formation of a stable SNARE complex.
  • the system may further comprise a detergent regardless of whether the head domain of syntaxin 3 is attached to the polypeptide derived from syntaxin.
  • a detergent can help to promote the assembly of the SNARE complex in the present invention.
  • the detergent is a mild detergent. Some assembly takes place in the absence of a detergent but the presence of a detergent promotes more efficient assembly of the SNARE complex.
  • the detergent is at a concentration above the critical micellar concentration (CMC) which is the concentration at which the detergent starts to form micelles.
  • the detergent has a carbon chain with a length of 7-12 carbon atoms.
  • the detergent is not Triton X-IOO or Thesit.
  • a suitable detergent can be selected from the group consisting of MEGA 8, C-HEGA 10, C-HEGA 11, HEGA 9, heptyl glucopyranoside, octylglucopyranoside, nonylglucopyranoside, zwittergent 3-08, zwittergent 3-10, and zwittergent 3-12.
  • the detergent is octylglucopyranoside.
  • one of the helices can be immobilised on a substrate.
  • the helix is immobilised on a substrate.
  • the helix can be immobilised in any suitable way and such ways are well known to those skilled in the art.
  • the helix may be immobilised via a linker.
  • the substrate can be any suitable substrate for immobilising the helix.
  • the substrate may be a surface, a matrix, a bead, a quantum dot, a resin, glass, a metal, a polymer, a microscope slide, an array or a nanotube such as a carbon naotube.
  • the helix that is immobilised on the substrate does not have a cargo moiety attached to it.
  • the complexing system can further comprise one polypeptide helix derived from complexin.
  • the complexin protein from which the polypeptide helix is derived can be any complexin protein which can bind to a SNARE complex.
  • the skilled person is aware of the various complexin proteins which can bind to a SNARE complex.
  • the complexin protein may be selected from mammalian complexin 1 or complexin 2 isoforms. Other preferable features and properties (e.g. size) of the helix derived from the complexin protein are the same as for the other helices.
  • the helix derived from complexin may optionally carry one or two cargo moieties.
  • the complexin moiety only binds to a formed SNARE complex, it can also be used to purify specifically an assembled complex.
  • the helix derived from complexin may comprise the sequence as shown in SEQ ID NO. 63.
  • the helix derived from complexin may consist of this sequence.
  • An alternative embodiment of the invention is directed to a SNARE complex in which the polypeptide helix derived from syntaxin is joined to the polypeptide helix derived from synaptobrevin or a homolog thereof.
  • a complexing system for forming a molecular scaffold comprising: two polypeptide helices derived from a SNAP protein;
  • polypeptide helix derived from synaptobrevin or a homolog thereof
  • polypeptide helices can form a stable SNARE complex and wherein the polypeptide helix derived from syntaxin is joined to the polypeptide helix derived from synaptobrevin or a homolog thereof.
  • This embodiment of the invention is directed to the three component system described above in which the polypeptide helix derived from syntaxin is joined to the polypeptide helix derived from synaptobrevin or a homolog thereof. It will be apparent to one skilled in the art that virtually all the description above relating to limitations and preferable features of the complexing system containing a helix which is less than 50 amino acids in length is equally applicable to the above system containing a polypeptide helix derived from syntaxin joined to a polypeptide helix derived from synaptobrevin or a homolog thereof.
  • the two helices derived from a SNAP protein in this system may also be joined together as described above to produce a two component system. The skilled person would appreciate that two of the helices do not need to be less than 50 amino acids in length.
  • a complexing system for forming a molecular scaffold comprising:
  • polypeptide helix derived from synaptobrevin or a homolog thereof
  • polypeptide helices can form a stable SNARE complex and wherein the polypeptide helices are joined together to form two helix containing components.
  • the two component system can be formed in two ways. First, two of the helices can be joined together and the other two helices can be joined together to form two components each comprising two helices.
  • three of the helices can be joined together to give a component containing three helices which can form a SNARE complex with the single remaining helix.
  • the invention provides a complexing system for forming a binary compound comprising two cargo moieties, the complexing system comprising:
  • binary compound means a compound which is made up of two separate parts (cargo moieties) so that when the two parts are brought together, the compound is able to carry out its function. The function of the compound will depend on the functions or identities of the two separate parts of the compound.
  • the first cargo moiety has a first function and the second cargo moiety has a second function.
  • the first cargo moiety may have an enzymatic or imaging function and the second cargo moiety may have a targeting function. This enables the compound to be targeted to a particular location at which the enzymatic or imaging part is able to carry out its function.
  • the enzymatic portion and the translocation portion can form one part (cargo moiety) and the receptor binding portion can form a second part (cargo moiety) so that when they are brought together by the complexing system, a functional botulinum toxin is formed.
  • tetanus, ricin and diptheria toxin can be separated into two parts so that when they are brought together, a functional toxin is formed.
  • the first cargo moiety has a first function and the second cargo moiety has a second function, which when brought together form a fully functional peptide, e.g. a toxin.
  • peptides which are formed from distinct units and can be used in the way described above is well within the capability of a person skilled in the art.
  • US2009/0035822 describes the formation of functional proteins from separate parts. Diptheria toxin, tetanus toxin and ricin can be used in therapy, for example, in the treatment of neoplastic disease. Therefore, complexing systems involving these polypeptides can be used in therapy and in the treatment of neoplastic disease. They can also be used in a method of treatment comprising administering an effective amount of a composition comprising the complexing system to a subject.
  • the present invention also provides a method of forming a SNARE complex to form a binary compound comprising two cargo moieties, the method comprising:
  • the invention provides a complexing system for forming a botulinum toxin comprising:
  • polypeptide helix derived from synaptobrevin or a homolog thereof
  • the four polypeptide helices can form a stable SNARE complex, wherein a first cargo moiety is attached to a first helix and a second cargo moiety is attached to a second separate helix, and wherein the first cargo moiety comprises the light chain of a botulinum toxin or a functional portion thereof and the translocation portion of the heavy chain of a botulinum toxin and the second cargo moiety comprises the receptor binding portion of the heavy chain of a botulinum toxin.
  • some of the diseases or conditions which are alleviated by the inhibition of neural synapses are selected from the group consisting of: excessive sweating, excessive salivation, dystonias, gastrointestinal disorders, urinary disorders, facial spasms, strabismus, cerebral palsy, stuttering, chronic tension headaches, hyperlacrymation, hyperhidrosis, spasms of the inferior constrictor of the pharynx, spastic bladder, pain, migraine, and cosmetic treatments such as reducing wrinkles, brow furrows, etc.
  • first cargo moiety is attached to a first helix and a second cargo moiety is attached to a second separate helix, wherein the first cargo moiety comprises the light chain of a botulinum toxin or a functional portion thereof and the translocation portion of the heavy chain of a botulinum toxin and the second cargo moiety comprises the receptor binding portion of the heavy chain of a botulinum toxin.
  • This method causes the two parts of the botulinum toxin to be brought together thus producing a fully functional botulinum toxin.
  • the present invention provides a component for forming a botulinum toxin, the component comprising: a polypeptide helix derived from: a SNAP protein; syntaxin; or synaptobrevin or a homolog thereof, wherein the polypeptide helix is attached to a cargo moiety comprising the light chain of a botulinum toxin or a functional portion thereof and the translocation portion of the heavy chain of a botulinum toxin.
  • the invention provides the use of the above components as well as a kit comprising two polypeptide helices derived from a SNAP protein; one polypeptide helix derived from syntaxin; and one polypeptide helix derived from synaptobrevin or a homolog thereof, wherein the four polypeptide helices can form a stable SNARE complex, wherein a first cargo moiety is attached to a first helix and a second cargo moiety is attached to a second separate helix, and wherein the first cargo moiety comprises the light chain of a botulinum toxin or a functional portion thereof and the translocation portion of the heavy chain of a botulinum toxin and the second cargo moiety comprises the receptor binding portion of the heavy chain of a botulinum toxin.
  • botulinum toxin can comprise further limitations and that the limitations described elsewhere with regard to other aspects and embodiments of the invention are equally applicable to these botulinum toxin embodiments.
  • the invention provides a complexing system for forming a molecular scaffold, the system comprising:
  • polypeptide helix derived from synaptobrevin or a homolog thereof
  • the four polypeptide helices can form a stable SNARE complex and wherein the SNARE complex is formed in the presence of a detergent.
  • Muncl ⁇ is thought to be a negative regulator of SNARE complex formation.
  • the inventors have surprising found that a detergent allows better SNARE complex formation in the absence of Muncl ⁇ .
  • the system does not contain a Muncl ⁇ protein.
  • the system is a Muncl ⁇ free system.
  • the present invention also provides the use of a detergent for promoting the assembly of a SNARE complex in the absence of Muncl ⁇ .
  • the detergent is a mild detergent.
  • the detergent is a synthetic detergent.
  • the detergent has a carbon chain length of 7-12 carbon atoms.
  • All the embodiments of the invention described above relate to a complexing system in which a single stable SNARE complex is produced with one or more cargo moieties attached to that SNARE complex. This is useful in a large number of applications, for example, diagnostics.
  • the system also has application in tagging applications for affinity purification of labelled proteins, immobilisation of proteins or cells, or identification of labelled proteins
  • affinity reagent assembly including combinatorial assembly, poly-, homo- and hetero- oligomerisation
  • drug small molecules, nucleic acids, proteins
  • targeting and internalisation signals with the cargo
  • binary compounds e.g. functional proteins, enzymes, factors, co-factors, (and any other functional proteins), FRET labels, binary inorganic compounds and small molecules, binary organic compounds;
  • the present invention provides the use of any of the embodiments of the complexing system described above and, in particular, in any of the applications described above.
  • the present invention provides the use of the complexing system in diagnostics, such as an array, an assay, a micro fluidic device, an SPR instrument, a QCM instrument, a mass spectrometer, an electrophoresis instrument, a chromatography column, a scanning probe microscope, or a calorimetry instrument.
  • the complexing system may be used in arrays to secure antibodies to a substrate.
  • the present invention provides an apparatus having a stable SNARE complex immobilised thereon, the SNARE complex comprising:
  • polypeptide helix derived from synaptobrevin or a homolog thereof
  • the apparatus is selected from an array, an assay, a microfluidic device, an SPR instrument, a QCM instrument, a mass spectrometer, an electrophoresis instrument, a chromatography column, a scanning probe microscope, and a calorimetry instrument.
  • the present invention also provides a method of forming a SNARE complex carrying one or more cargo moiety, the method comprising:
  • polypeptide helix derived from syntaxin is joined to the polypeptide helix derived from synaptobrevin or a homolog thereof;
  • At least two of the polypeptide helices are less than 50 amino acids in length.
  • the present invention also provides a component comprising a polypeptide helix derived from syntaxin joined to a polypeptide helix derived from synaptobrevin or a homolog thereof and wherein the two joined helices can form part of a stable SNARE complex.
  • the two helices are joined together so that they can assemble into the same stable SNARE complex.
  • the two helices may be joined together so that they cannot assemble into the same stable SNARE complex.
  • the two helices should be able to assemble into different stable SNARE complexes.
  • the two helix component of the invention comprising a helix derived from syntaxin and a helix derived from synaptobrevin or a homolog thereof may comprise one of the following sequences shown in SEQ ID NO. 12, 13, 14 and 73.
  • the two helix component of the invention comprising a helix derived from syntaxin and a helix derived from synaptobrevin or a homolog thereof may consist of one of the above sequences.
  • the two helix component may further comprise one or more cargo moieties attached to the polypeptide helices.
  • the present invention also provides a component comprising two polypeptide helices derived from a SNAP protein and either a polypeptide helix derived from synaptobrevin or a polypeptide helix derived from syntaxin, wherein the three helices are joined together to form a tri-helical component and wherein the three joined helices can form part of a stable SNARE complex.
  • the third helix is derived from synaptobrevin.
  • the three helices are joined together so that they can assemble into the same stable SNARE complex.
  • a tri-helical component of the invention comprising SNAP-25 helices and a helix derived from synaptobrevin or a homolog thereof may comprise SEQ ID NO. 15. Further, the tri-helical component may consist of this sequence.
  • the three helices may be joined together so that the two SNAP helices can assemble into the same stable SNARE complex but the third helix cannot assemble into the same stable SNARE complex as the two SNAP helices.
  • the third helix should be able to assemble into a different stable SNARE complex compared to the two SNAP helices.
  • the tri-helical component may further comprise one or more cargo moieties attached to the polypeptide helices.
  • the present invention provides the use of the above components, for example, to form a stable SNARE complex for forming a molecular scaffold.
  • the present invention further provides a kit comprising a component comprising a polypeptide helix derived from syntaxin joined to a polypeptide helix derived from synaptobrevin or a homolog thereof and wherein the two joined helices can form part of a stable SNARE complex.
  • the kit may further comprise two polypeptide helices derived from a SNAP protein which can form a stable SNARE complex with the syntaxin/synaptobrevin derived helices. The two SNAP helices may be joined together.
  • the present invention provides a kit comprising a component comprising two polypeptide helices derived from a SNAP protein and either a polypeptide helix derived from syntaxin or a polypeptide helix derived from synaptobrevin, wherein the three helices are joined together to form a tri-helical component and wherein the three joined helices can form part of a stable SNARE complex.
  • the kit may further comprise a single polypeptide helix derived from the fourth SNARE protein.
  • the kit may further comprise a single polypeptide helix derived from syntaxin which can form a stable SNARE complex with the joined SNAP/synaptobrevin derived helices.
  • the kit may further comprise a single polypeptide helix derived from synaptobrevin or a homolog thereof which can form a stable SNARE complex with the joined SNAP/syntaxin derived helices.
  • kits of the invention may further comprise suitable reagents for use with the kit. Further features of the helices and the SNARE complex of the kit are as described above.
  • the complexing system can also be used to form multimers of SNARE complexes.
  • This is a plurality of SNARE complexes joined together.
  • two of the helices are joined together in such a way so that they cannot form a stable SNARE complex in the same complex.
  • the two helices should be joined together in such a way so that they can each form a stable SNARE complex but in different SNARE complexes. This may be done by joining the helices directly together without any kind of linker so that the two helices cannot take up the correct conformation in the same SNARE complex. Instead, each helix in such a 2-helical joint construct can complex with the three other polypeptide helices to form two stable SNARE complexes.
  • the two helices can be joined together in any suitable way, for example, by recombinant means or chemical coupling. Take, for example, a two component system in which the two helices derived from a SNAP protein are joined together and the two helices derived from syntaxin and synaptobrevin are joined in a restricted manner so that they cannot assemble in the same SNARE complex. Starting with a syntaxin-synaptobrevin fusion protein, the SNAP fusion protein will complex with the syntaxin helix. A synaptobrevin helix from another syntaxin-synaptobrevin fusion protein will then bind to the SNAP-syntaxin complex to form a four -helical SNARE complex.
  • This complex will have a syntaxin helix and a synaptobrevin helix protruding from it, one from each of the syntaxin-synaptobrevin fusion proteins. These single helix protrusions can be the basis for the formation of further SNARE complexes. Therefore, a multimer of SNARE complexes is formed. In the above example, the SNAP helices do not have to be joined together. Further, any two helixes could be joined together for the system to work as long as they both cannot assemble in the same complex to form a stable SNARE complex. The present invention also provides a multimer produced by the above system.
  • a multimer can be formed by controlling the reaction conditions of the system. Two of the helices of the system must be joined together. This can be done in any suitable way. The two helices do not need to be restricted in any way as in the above example although they can be, if desired.
  • the system further comprises a single helix which is derived from the same SNARE protein as one of the two joined helices.
  • the system further comprises a single syntaxin helix.
  • the single syntaxin helix is introduced into a solution. This single helix may be free in the solution or immobilised on a substrate, as discussed above.
  • Two helices derived from a SNAP protein (which may or may not be joined) are added to the solution. These bind to the syntaxin helix to form a syntaxin-SNAP tri- helical complex. After this, the syntaxin-synaptobrevin fusion protein is added to the solution. The synaptobrevin helix from this fusion protein binds to the tri-helical complex to form a stable SNARE complex whilst the syntaxin helix will remain unbound and will protrude from the SNARE complex. By going through the same steps as above repeatedly, this syntaxin protrusion can be used to form further SNARE complexes, thus producing a multimer. Since the above system requires the helices to be added in a particular order, it may be necessary to ensure that there are no unwanted molecules after a particular step. This can be done, for example, by immobilizing the single syntaxin helix and performing washing after each binding step.
  • the present invention also provides a multimer produced by the above system.
  • each SNARE complex comprises:
  • polypeptide helix derived from synaptobrevin or a homolog thereof
  • a helix from one SNARE complex is joined to a helix from another SNARE complex to join the SNARE complexes together, and wherein one or more cargo moiety is attached to the polypeptide helices.
  • the multimer of the present invention can be linear. If it is linear, each SNARE complex will be attached to two other SNARE complexes on either side to form a long linear chain similar to a string of beads. Therefore, two of the helices in a SNARE complex will be attached to a helix in two different SNARE complexes. Obviously, the SNARE complexes at the end of the chain will only be attached to one other SNARE complex by one polypeptide helix.
  • the multimer may be branched. This can be done, for example, by joining a synaptobrevin derived helix to two syntaxin derived helices in any order.
  • synaptobrevin derived helix from this triple joined construct will attach to a syntaxin/SNAP derived tri-helical intermediate to form a SNARE complex with the two syntaxin derived helices left unbound.
  • a SNAP derived helices are added, for example, SNAP-25
  • two joint syntaxin/SNAP-25 intermediates will form.
  • two joint SNARE complexes will form with two syntaxin derived helices protruding. This will seed two branches for further growth. Therefore, joining three helices allows branching (in contrast to two joint helices which are used for linear polymerization).
  • one SNARE complex within the multimer will be attached to three other SNARE complexes to form a branch point rather than being attached to two other SNARE complexes, as in a linear chain.
  • Three of the helices in the SNARE complex at the branch point will be attached to a helix in three different SNARE complexes.
  • the multimer can have a cargo moiety attached to the end of each of the helices.
  • the multimer may have a plurality of cargo moieties attached to the multimer at the end of the helices.
  • the multimer may have a cargo moiety on each SNARE complex.
  • the multimer may have a plurality of cargo moieties attached to each SNARE complex. If the multimer has a plurality of cargo moieties, these may be the same or different.
  • the present invention also provides a method of producing a multimer, the method comprising the following steps: 1) providing a first polypeptide helix derived from a first SNARE helix;
  • Steps 2) and 3) can be repeated as many times a necessary to produce a multimer of the required length.
  • the above method refers to a first, second, third and fourth SNARE helix.
  • the SNARE complex is formed from four helices. Two of these helices are provided by a SNAP protein, one is provided by syntaxin and one is provided by synaptobrevin or a homolog thereof. Therefore, in the above method, these four helices, in no particular order, are the first, second, third and fourth SNARE helices. This is because the identity of a particular helix is not important as long as the four helices are used in the SNARE complex.
  • the SNARE complex may also be bound to complexin, as described above.
  • the first helix is a syntaxin derived helix
  • the second helix is a SNAP derived helix
  • the third helix is a SNAP derived helix
  • the fourth helix is a synaptobrevin derived helix
  • the fifth helix is a syntaxin derived helix. Due to the fact that the four helices can be used in the SNARE complex in any order, the fifth polypeptide helix does not need to be derived from the same SNARE helix as the first polypeptide helix. Similarly, when forming the second, third, fourth, fifth, sixth, etc.
  • the second, third and fourth polypeptide helices do not need to be derived from the same SNARE helix as the second, third and fourth polypeptide helices in the first SNARE complex.
  • the only requirement is that all four SNARE helices are represented in each SNARE complex so that a stable SNARE complex forms.
  • polypeptide helices in the first cycle of steps, one of the polypeptide helices derived from a SNAP protein could be a full length SNAP-25 helix whereas in the second cycle of steps, this polypeptide helix could be a SNAP-25 helix which is 45 amino acids in length.
  • the important aspect is that both polypeptide helices are derived from the same SNARE helix, e.g. a particular SNAP helix, so that all four SNARE helices are represented in the SNARE complex.
  • One or more cargo moiety is attached to the polypeptide helices so that the resulting multimer has a cargo moiety attached to it.
  • This can be done by attaching a cargo moiety to the polypeptide helices before being used in the method.
  • the cargo moiety is attached at the end of the polypeptide helix.
  • a plurality of cargo moieties can be introduced into the multimer. This can be done by attaching a cargo moiety to a number of polypeptide helices which are then incorporated into the multimer using the above method.
  • the cargo moieties may be the same or different.
  • the identity of the first, second, third and fourth SNARE helices are maintained in the repeated steps. So, for example, if, in the first cycle of steps which produce the first SNARE complex, the first SNARE helix is syntaxin, the second and third SNARE helices are from a SNAP protein, and the fourth SNARE helix is synaptobrevin or a homolog thereof, in subsequent cycles of steps which produce further SNARE complexes, the first SNARE helix is always syntaxin, the second and third SNARE helices are always from a SNAP protein, and the fourth SNARE helix is always synaptobrevin or a homolog thereof.
  • the identity of the second, third, fourth and fifth polypeptide helices are maintained in the repeated steps. So, for example, if, in the first cycle of steps which produce the first SNARE complex, the second and third SNARE helices are from a SNAP protein, the fourth SNARE helix is from a synaptobrevin
  • the fifth polypeptide helix (which forms the first helix in the next SNARE complex) is always a syntaxin
  • the second and third SNARE helices are always from SNAP-25
  • the fourth SNARE helix is always a synaptobrevin SNARE helix.
  • the second and third polypeptide helices are joined together so that they can assemble together in the same SNARE complex.
  • the second and third polypeptide helices are a full length SNAP protein, e.g. SNAP-25.
  • the first polypeptide helix is immobilised on a substrate.
  • Suitable substrates are well known to those skilled in the art and are discussed above.
  • the method may further comprise the step of washing after each binding step to remove any unbound helices. This ensures that these unbound helices cannot interfere with the formation of the multimer in subsequent steps.
  • the multimer that is being formed by the method is immobilised before a washing step is used.
  • the method may be modified to introduce a branch into the multimer.
  • a sixth polypeptide helix derived from a first SNARE helix is joined to one of the second, third, fourth or fifth polypeptide helices to provide a helix upon which another stable SNARE complex can be formed.
  • the sixth polypeptide helix is joined to the second or third polypeptide helices.
  • the sixth polypeptide helix is joined to the fourth or fifth polypeptide helix. This allows two further SNARE complexes to originate from a particular SNARE complex, thereby introducing a branch in the multimer.
  • a synaptobrevin derived helix can be joined to two syntaxin derived helices in any order, as discussed above.
  • a syntaxin helix can be joined to SNAP-25 (being the second and third helix) to start the formation of a second SNARE complex from the originating SNARE complex, meaning that the originating SNARE complex will be attached to three other SNARE complexes overall to form a branch point.
  • multiple branches can be introduced at a particular SNARE complex by introducing further helices in addition to the sixth helix which are joined to the other helices of the SNARE complex.
  • a synaptobrevin derived helix can be joined to three or more syntaxin derived helices in any order.
  • two or more syntaxin helices can be joined to SNAP-25 (being the second and third helix) to start the formation of a third, fourth, etc.
  • SNARE complex from the originating SNARE complex meaning that the originating SNARE complex will be attached to four or more other SNARE complexes overall to form a multiple branch point.
  • many branches as necessary can be introduced into the multimer at one particular point and over the length of the multimer.
  • the present invention also provides a multimer produced by the above method.
  • the multimer described above is useful in a large number of applications, for example, diagnostics and the applications described below:
  • drug small molecules, nucleic acids, proteins
  • multimeric compounds e.g. functional proteins, enzymes, factors, co-factors, (and any other functional proteins), FRET labels, multimeric inorganic compounds and small molecules, multimeric organic compounds;
  • nanowires e.g. gold plated glass slides
  • thin films e.g. gold plated glass slides
  • wires e.g. nanowires
  • nanotubes surface modifications e.g. nanotubes surface modifications.
  • Figure 1 is a schematic representation of the molecular machinery which drives vesicle fusion in neurotransmitter release.
  • the core SNARE complex is formed by four ⁇ -helices contributed by synaptobrevin, syntaxin and SNAP- 25.
  • Synaptotagmin serves as a calcium sensor and regulates intimately SNARE zipping during vesicle fusion.
  • Figure 4 is an SDS-PAGE gel showing that 45 amino acid polypeptides were able to form the irreversible SNARE complex (panel A), while 40 amino acids peptides did not (panel B).
  • the inventors call this assembly TetriCS (Tetrahelical Combinatorial Scaffold).
  • Figure 5 is a graph showing that streptavidin could bind 45 aa Tetrics peptides attached to either glutathione or Nickel beads in a highly specific manner.
  • Figure 6 is a schematic representation of a 3 -component SNARE bundle comprising the full-length SNAP-25 molecule (amino acids 1-206) which has two SNARE helices and separate syntaxin and synaptobrevin SNARE helices.
  • Figure 7 is an SDS-PAGE gel showing that both 40 (panel A) and 45aa (panel B) peptides can assemble with SNAP25B, demonstrating that in the 3 -component system, peptides of 40 aa length are sufficient for irreversible binding to full-length SNAP-25.
  • Figure 8 is a graph showing that control reactions with GST-SNAP-25 alone on beads exhibited negligible binding, whereas addition of 40 aa syntaxin and synaptobrevin peptides, carrying Myc-tag and S-tag respectively, led to formation of 3 -component complex as evidenced by a robust binding of both anti-Myc antibody and S-protein to glutathione beads.
  • Figure 12 is an SDS-PAGE gel showing that a syntaxin3-synaptobrevin2 fusion protein and rat SNAP-25B quickly assemble into an irreversible complex.
  • Figure 13 is a schematic representation showing the head domain and the SNARE motif of rat syntaxin3 (amino acids 1-260) fused via a short stretch of amino acids to rat synaptobrevin2 sequence 1-84.
  • Figure 14A is an SDS-PAGE gel showing that octylglucopyranoside can 'open' the syntaxin 3 molecule to allow a 2-component assembly to form.
  • Figure 14B is an SDS-PAGE gel showing that octylglucopyranoside detergent promotes the assembly of a tight SNARE complex at concentrations above CMC (critical micellar concentration - for this detergent, the CMC is 0.6%). Some assembly does take place in the absence of the detergent, but efficient assembly requires the detergent octylglucopyranoside to 'open' the syntaxin 3 molecule to allow a 2-component assembly to form.
  • Figure 15 is a Surface Plasmon Resonance Sensogram showing binding of syntaxin-synaptobrevin fusion protein (*) and the unique resistance of the assembly between the syntaxin/synaptobrevin fusion protein and SNAP-25 immobilized on the CM5 chip. Washes using 2M NaCl (1), glycine pH 2.5 (2), 1% SDS (3), 0.1 M NaOH (4), 0.1 M phosphoric acid (5) cannot break the binary capture reagent. Note, step 3 was repeated twice.
  • Figure 16A is a schematic representation of a 2-component SNARE bundle comprising a three-helical molecule (black) and a forth helix (grey).
  • Figure 16B is an SDS-PAGE gel showing that both 40 and 45aa syntaxin IA peptides can assemble with the three- helical fusion protein composed of SNAP-25B and synaptobrevin 2 (SNAP-25B(22-206)/Syb2(l-84)) demonstrating that in a two- component system, peptides of 40 aa length are sufficient for irreversible SNARE complex formation.
  • the SDS-resistant complex migrates faster than the tri-helical protein in the SDS-gel, possibly due to its compact structure.
  • Figure 17 is an SDS-PAGE gel showing that GST-SNAP-25 can bind to the Sepharose beads carrying syntaxin3/synaptobrevin2 fusion protein in a highly specific manner.
  • the syntaxin3/synaptobrevin2 fusion protein is covalently attached to BrCN-Sepharose beads and therefore cannot be eluted and visualised on the SDS_PAGE gel.
  • lane 1 - bacterial extract produced using zwitergent 3-08.
  • lane 2 - GST-SNAP-25 purified on beads carrying syntaxin3/synaptobrevin2 fusion protein.
  • Figure 18 is a schematic representation of a supramolecular device in the form of strong linear multimers of unlimited length formed by SNARE proteins.
  • Figure 19 is a schematic representation of the process of forming a long linear multimer using SNARE proteins.
  • FIG. 20 (A) Coomassie-stained gel showing a step-wise increase in the amounts of both syntaxin3- synaptobrevin2 fusion and SNAP-25 bound to beads. Note, while the amount of GST-syntaxin3, used for attachment to beads, remains constant there is a gradual increase in the amounts of bound SNAP-25 and syntaxin3- synaptobrevin2 fusion protein. To show the amounts of bound material, the samples were boiled to disrupt SDS- resistant nature of the assemblies. (B) As in panel A, but samples were not boiled prior to SDS-PAGE. Note the increase in the molecular weight of SDS-resistant polymers in line with extra polymerization steps.
  • Figure 21 is a schematic representation of a branched multimer formed from SNARE proteins.
  • SNAP25 (green and red) allows linking of Q-dot to Hc.
  • c Coomassie-stained SDS-gel showing an irreversible assembly of Hc-synaptobrevin, SNAP25 and biotinylated syntaxin3 peptide into an SDS-resistant complex, Hc-SNARE-biotin.
  • d Hc-SNARE-Q-dots exhibit synaptic binding as evidenced by the immunostaining for the synaptic vesicle marker synaptophysin at axonal extensions of cultured hippocampal neurons. Omission of SNAP25 during assembly prevents targeting of Q-dots to synaptic terminals.
  • c, LcHN, tagged with SNAP25 can be united with Hc, tagged with synaptobrevin, upon addition of the syntaxin3 peptide as evidenced by the Coomassie- stained and fluorescently-imaged SDS-gels.
  • Figure 26 shows that SNARE-linked botulinum neurotoxin exhibits synaptic localization and cleaves its intrasynaptic target
  • a Fluorescein-labelled LcHN-SNARE-Hc binds to axonal extensions of hippocampal neurons.
  • Immunostaining with anti-synaptophysin antibody highlights presynaptic terminals of cultured hippocampal neurons
  • b Immunoblot showing cleavage of intrasynaptic SNAP25 by the assembled neurotoxin in a similar fashion as the native BoNT/A.
  • Figure 27 shows that SNARE-linked botulinum neurotoxin inhibits neurotransmitter release, a, Fluorometric measurements of glutamate release from isolated rat brain synaptic endings (synaptosomes) indicate a similar degree of inhibition between LcHN- SNARE-Hc and BoNT/A.
  • Figure 28 shows LcHn was tagged by syntaxin3 (195-253) whereas Hc was tagged by synaptobrevin (25-84).
  • the two botulinum parts were mixed in the presence of SNAP-25 and the toxin formation was visualised on Coomassie- stained SDS-gel.
  • Figure 29 shows blockade of glutamate release from rat brain synaptosomes was assessed after 1 hour incubation with LcHnSyx3-SNAP25-synaptobrevinHc toxin from panel A.
  • Figure 30 shows cleavage of intraneuronal target of the catalytic part Lc after application of toxin LcHnSyx3- SNAP25-synaptobrevinHcA from panel A on hippocampal neurons was assessed by immunoblotting using anti- SNAP-25 antibody.
  • the reassembled toxin has similar activity in cleaving SNAP-25 as the native botulinum neurotoxin (BoNT/A).
  • BoNT/A botulinum neurotoxin
  • LcHnSyx3-SNAP25-synaptobrevinHcA is more efficient than LcHnSyx3-SNAP25- synaptobrevinHcD in this neuronal assay.
  • Figure 31 shows SNARE tagging of synaptobrevin 40 amino acid motif with somatostatin peptide
  • somatostatin peptide Ac- RLQQTQAQVDEWDIMRVNVDKVLERDQKLSELDDRADAL-Ahx-Ahx-AGCKNFFWKTFTSC-OH allows making of somatostatin-quantum dots. Streptavidin-coated quantum dots were incubated with biotynylated syntaxin peptide and then mixed with somatotostatin-synaptobrevin and SNAP-25.
  • the assembled somatostatin-Q-dots were applied on cultured hippocampal neurons and their entry into neuronal somas was visualised by fluorescence of Q- dots and counterstaining with anti-SNAP-25 antibody which labels the abundant intraneuronal protein.
  • Figure 32 shows SNARE tagging of synaptobrevin 40 amino acid motif with somatostatin peptide allows making of functional somatostatin-botulinum construct after mixing with LcHnsyntaxin3 and SNAP-25.
  • the activity of the LcHnsyntaxin3-SNAP25-synaptobrevinSomatostatin (SS-LcHN) was assessed by cleavage of SNAP-25 in cultured hippocampal neurons after 20 hour application of the assembled toxin.
  • Figure 33 is an SDS-gel showing formation of stable SDS-resistant complexes using SNARE motifs with N- terminal truncation.
  • Figure 34 is an SDS-gel showing formation of stable SDS-resistant complexes using SNARE motifs with C-terminal truncation.
  • Figure 35 is an SDS-gel showing formation of stable SDS-resistant complexes using a syntaxin SNARE peptide in which the internal methionines have been replaced with non-oxidizable norleucines.
  • Figure 36 is a number of SDS-gels showing formation of stable SDS-resistant complexes using a variety of different SNARE peptides.
  • Figure 37 is an SDS-gel showing formation of stable SDS-resistant complexes using three shortened SNARE peptides.
  • Figure 38 is an SDS-gel showing formation of stable SDS-resistant complexes using three shortened SNARE peptides.
  • Figure 39 is an SDS-gel showing formation of stable SDS-resistant complexes using three shortened SNARE peptides.
  • Figure 40 is an SDS-gel showing formation of stable SDS-resistant complexes when a neuropeptide is complexed to one of the SNARE peptides.
  • Figure 42 is an SDS-gel showing formation of stable complexes using SNARE peptides containing less than 40 amino acids.
  • Figure 43 is an SDS-gel showing maleimide-based cross linking of a protein to the SNARE peptides.
  • Figure 44 is a chart showing absorbance at 650nm for the TMB (3,3',5,5'-tetramethylbenzidine) substrate.
  • Figure 45 is a portion of a film showing luminescence.
  • the inventors have developed a method for linking functional or structural units by simple mixing. Generation of well-defined, functional supramolecular architectures of nanometric size through self-assembly provide means for performing programmed engineering in life biosciences, medicine and nanotechnologies. Specifically, the invention relates to the unmet need for a controlled linking of multiple functional units in an irreversible and site-specific manner as bundles or linear multimers as depicted in Figure 2.
  • SNARE proteins for linking protein domains, and in fact any conceivable chemical entities.
  • these proteins drive fusion of vesicles to the plasma membrane by forming a tripartite complex composed of syntaxin, SNAP-25 and synaptobrevin (also known as VAMP - vesicle-associated membrane protein).
  • This SNARE complex is a 4-helical coiled-coil bundle comprising two helices from SNAP-25, one helix from syntaxin and one helix from synaptobrevin (Fig. 3); the length of each helix being ⁇ 60-70 amino acids (Jahn and Scheller (2006)).
  • This 4-helical bundle is unusually stable, even in SDS - a direct indication of the irreversible nature of SNARE assembly (Hu, K et al., 2002).
  • a coiled coil for various applications depends on several characteristics: the length of the coiled coil polypeptides, their solubility, their ability to allow homo- or hetero-oligomerization; and the strength of the coiled coil, i.e. ability to withstand dissociation in normal and adverse conditions.
  • the unique properties of the SNARE coiled-coil bundle such as hetero-tetramerization and the irreversible nature of SNARE assembly have not been considered yet for exploitation.
  • the core idea of using the SNARE bundle relates to the means of producing diagnostic/therapeutic/biotechnological protein which must carry a combination of different cargoes (fluorescent, radioactive, immune, chemical, affinity, etc.).
  • the inventors have proposed using engineered polypeptides, based on the syntaxin, SNAP-25 and synaptobrevin proteins, for production of well- defined, organised heterotetrameric supramolecular architectures capable of self-assembly from distinct individual components.
  • the inventors first define the minimal core for the 4- and 3-component bundles; second, the inventors describe a 2-component capture system for irreversible binding; and, third, the inventors show the usefulness of the SNARE bundle to produce linear multimers.
  • shortened SNARE helices can be used for assembly of functional units as a 4-component bundle.
  • Use of shortened SNARE helices is essential for attachment of chemical entities to the SNARE peptides via a synthetic route.
  • peptide synthesis is sufficiently reliable and financially feasible for ⁇ 50 amino acids. Therefore, it would be advantageous if SNARE helices are shortened allowing attachment of further peptide sequences or other chemical entities. It is known that shortening of a single SNARE motif can lead to disruption of irreversible SNARE assembly (Hao et al., 1997).
  • TetriCS peptides containing either 40 or 45 amino acids.
  • Rat SNAP25A Helix 2 (amino acids 149-188) with 6-Histidine tag:
  • Rat Synaptobrevin-2 (amino acids 31-70) with the S-tag epitope for monoclonal antibody recognition:
  • Rat SNAP25A Helix 1 (amino acids 28-72) with biotin:
  • biotin-STRRMLQLVEESKDAGIRTLVMLDEQGEQLDRVEEGMNHINQDMKC SEQ ID NO. 5
  • Rat SNAP25A Helix 2 (amino acids 149-193) with a cysteine and 6-Histidine tag:
  • Rat SyntaxinlA (amino acids 201-245) with an N-terminal antibody epitope and a cysteine:
  • the functionality of the assembly was tested in pull-down experiments.
  • the inventors used GST-tagged synaptobrevin (45 amino acid SNARE sequence, produced recombinantly in bacteria), biotin chemically linked to Helix 1 of SNAP-25 and 6-Histidine tag linked to Helix 2 of SNAP-25 as functional units.
  • the inventors tested binding of the TetriCS assembly to glutathione beads (for GST binding) or Nickel beads (for binding the 6-Histidine tag) followed by binding of fluorescent streptavidin (for binding to biotin).
  • Fig. 5 shows that streptavidin could bind 45 aa TetriCS attached to either glutathione or Nickel beads in a highly specific manner.
  • TetriCS allows the development of functional supramolecular devices, defined as structurally organised and functionally integrated systems built from suitably designed molecular components performing a given action (Lehn, 2007).
  • Fig. 7 shows that both 40 (panel A) and 45aa (panel B) peptides can assemble with SNAP25B, demonstrating that in the 3-component system, peptides of 40 aa length are sufficient for irreversible binding to full-length SNAP-25.
  • EIIKLENSIRELHDMFMDMAMLVESQGEMIDRIEYNVEHA-GSGEQKLISEEDLC (SEQ ID NO. 9)
  • Synthetic synaptobrevin-S-tag peptide (40 amino acids synaptobrevin sequence in bold)
  • RLQQTQAQVDEWDIMRVNVDKVLERDQKLSELDDRADAL-GSKETAAAKFERQHMDS (SEQ ID NO. 9)
  • the inventors next used Surface Plasmon Resonance technique to test the ability of the 40aa 3 -component TetriCS to withstand harsh treatment.
  • the inventors chemically attached GST-tagged SNAP-25B to the Biacore CM5 chip, followed by binding of the 40 aa syntaxin and synaptobrevin peptides and then of the antibody.
  • Fig. 9 shows that the binding of peptides is stable and allows attachment of anti-myc antibody to the surface of the chip. Addition of 0.1% SDS removed the antibody but not the peptides from the immobilised SNAP-25.
  • Example 3 2-component bundle
  • the inventors also simplified the irreversible SNARE assembly to a 2-component system.
  • Two-component affinity- based tools underlie all basic research and are invaluable in the development of drugs and diagnostics (Uhlen, 2008).
  • Applications include affinity chromatography, microarray technologies, microplate-based screens and many biotechnology processes.
  • the main factor underlying successful outcome of these applications relies on a firm, irreversible immobilization of a protein in a defined orientation on either a solid surface or three-dimensional matrix.
  • Several recent reviews highlighted a number of disadvantages of existing immobilization technologies (Kohn, 2009; Tomizaki et al., 2005).
  • the inventors used a de-novo designed syntaxin/synaptobrevin fusion protein together with the 2-helical SNAP-25 (see Fig 10).
  • the inventors linked rat syntaxinlA SNARE motif (amino acids 195-254) with the rat synaptobrevin2 SNARE motif (aa 25-84) as illustrated in Figure 11.
  • the short stretch of amino acids between the syntaxin and synaptobrevin sequences (GILDSMGRLELKL (SEQ ID NO. 10), a small arrow) is due to a multiple cloning site in the hybrid plasmid.
  • the inventors purified the fusion protein but found that it had a tendency to aggregate via the syntaxin 1 motif preventing formation of SNARE complexes with SNAP-25.
  • the inventors produced a fusion of rat syntaxin3 with synaptobrevin2.
  • the inventors fused the SNARE motif of rat syntaxin3 (amino acids 195-253) via a short stretch of amino acids to rat synaptobrevin2 sequence 1-84.
  • the short stretch of amino acids between the syntaxin and synaptobrevin sequences (GILDSMGRLELKL) is due to a multiple cloning site in the hybrid plasmid allowing insertion of functional units between syntaxin3 and synaptobrevin2.
  • this syntaxin3-synaptobrevin2 fusion protein quickly assembled into an irreversible complex as illustrated in Fig. 12.
  • rat syntaxin3 amino acids 1 - 260 fused via a short stretch of amino acids to rat synaptobrevin2 sequence 1-84 (see Fig 13).
  • the short stretch of amino acids between the syntaxin and synaptobrevin sequences (GILDSMGRLELKL (SEQ ID NO. 10)) is due to a multiple cloning site in the hybrid plasmid allowing insertion of functional units between syntaxin3 and synaptobrevin2.
  • the inventors have also found that other detergents or similar lipid compounds have the same effect, such as MEGA 8, C-HEGA 10, C-HEGA 11, HEGA 9, heptylglucopyranoside, octylglucopyranoside, nonylglucopyranoside, zwittergent 3-08, zwittergent 3-10 and zwittergent 3-12.
  • the inventors have produced a binary affinity reagent with one small tag in which a short syntaxin helix ( ⁇ 5 kDa) can bind irreversibly to a de novo-designed tri-helical SNARE fusion protein (-27-31 kDa) represented schematically in Fig. 16A.
  • a short syntaxin helix ⁇ 5 kDa
  • a de novo-designed tri-helical SNARE fusion protein represented schematically in Fig. 16A.
  • the inventors fused the two SNAP-25 SNARE helices (22-206 amino acids) to the SNARE motif of synaptobrevin2 sequence 1-84.
  • the linker GSGSEQKLISEEDLG SEQ ID NO. 11 between the SNAP-25 and synaptobrevin sequences carries a myc-tag epitope.
  • the tri-helical fusion protein When mixed with syntaxin 40 or 45 amino acids peptides, described earlier, the tri-helical fusion protein quickly assembled into an irreversible complex as illustrated in Fig. 16B.
  • These two-component systems are useful alternatives to current affinity tags (Terpe, 2003).
  • Both tags in the binary capture systems can be expressed in bacteria and easily added, in a site-specific manner, to any protein for recombinant production - this is different from biotin/streptavidin or similar very high affinity systems (biotin can not be expressed as part of the protein).
  • Fast capture from highly diluted solutions is now possible due to the irreversible nature of the binary affinity reagents - no other such system currently exists.
  • either of the tags in the binary system can be chemically linked to surfaces of beads, chips, microarray plates, and modified by chemical or recombinant introduction of functional groups.
  • the inventors first immobilized to BrCN-Sepharose beads the two-helical fusion protein containing the SNARE motif of rat syntaxin3 (amino acids 195-253) fused via a short stretch of amino acids to rat synaptobrevin2 sequence 1-84
  • GST glutathione-S-transferase
  • Fig. 17 shows that GST-SNAP-25 can bind to the Sepharose beads carrying syntaxin3/synaptobrevin2 fusion protein in a highly specific manner.
  • SNARE proteins In addition to attaching multiple groups in a bundled fashion, SNARE proteins also offer a possibility of producing advanced supramolecular devices in the form of strong linear multimers of unlimited length as depicted in Figure 18.
  • the inventors' assembly represents a unique approach in which biomaterials are assembled molecule by molecule to produce novel linear supramolecular architectures (for overview of possible applications (Hinman et al., 2000; Lehn, 2007; Ryadnov and Woolfson, 2003; Zhang, 2003)).
  • the inventors used the syntaxin3-synaptobrevin2 fusion protein described above for the 2-component system (rat syntaxin 3 (amino acids 1-260) fused via a short stretch of amino acids to rat synaptobrevin2 sequence 1- 84).
  • the inventors instead of mixing SNAP-25 and the syntaxin3-synaptobrevin2 fusion in solution, the inventors used a solid support with a single syntaxin3 polypeptide with the head domain (amino acids 1-260 fused to GST) to initiate the polymerization reaction. The inventors first immobilized the GST-syntaxin3 molecule alone on glutathione beads via a GST tag.
  • Figure 2OA shows the step-wise increase in the amounts of both syntaxin3-synaptobrevin2 fusion and SNAP-25 over the course of the above process. While the amount of GST-syntaxin3, used for attachment to beads, remains constant there is a gradual increase in the amounts of bound SNAP-25 and syntaxin3-synaptobrevin2 fusion protein. To show the amounts of bound material, the samples were boiled to disrupt SDS-resistant nature of the assemblies.
  • Figure 2OB shows the increase in the molecular weight of SDS-resistant polymers in line with extra polymerization steps as the samples were not boiled prior to SDS-PAGE.
  • SNAP-25 and syntaxin3-synaptobrevin represent building blocks for controlled fabrication of diverse molecular structures.
  • Applications include fabrication of functionalised nanofibers, multiple ligand mcroarrays, supermolecular enzyme assemblies, new electronic devices and biomaterials for use in biotechnology and medicine (for overview of possible applications (Zhang, 2003)).
  • the 2-component system described above also allows multimerization in solution, which presents a way to link 1 to 4 protein functional domains in a linear fashion.
  • the protein-based fabrication of fully SDS- resistant linear polymers can be used for creation of biodegradable fibres with properties superior to silk spider multi-component assemblies or current coiled-coil nanofibers.
  • Example 5 SNARE tagging allows a step-wise assembly of botulinum neurotoxins
  • Fusing the receptor-binding domain with synaptobrevin SNARE motif allowed delivery of the active part of botulinum neurotoxin, tagged with SNAP25, into neurons.
  • the data show that SNARE-tagged toxin was able to cleave its intra-neuronal molecular target and inhibit release of neurotransmitters.
  • SNARE Soluble N-ethylmaleimide sensitive factor Attachment protein REceptor
  • the four SNARE motifs are 55 amino acids long carrying eight characteristic heptade repeats.
  • the brain SNARE complex is extraordinary in its stability exhibiting resistance to chaotropic agents, strong detergents, proteases and elevated temperatures.
  • the inventors decided to investigate whether fusing the SNAREs to recombinant proteins would allow a controlled building of a supramolecular entity.
  • Botulinum NeuroToxin type A (BoNT/ A) has proven to be of great medical importance due to its ability to cause a very long neuromuscular paralysis upon local injections of minute amounts (1 pM concentration) (Montecucco, C. et al. (2009)).
  • BoNT/A is a 150 kDa protein consisting of three main modules: 50 kDa catalytic part (Light chain, Lc) which is joined via a disulphide bridge to so-called Heavy chain which in turn made of the N-terminal 50 kDa translocation part (HN) and the C-terminal 50 kDa part (Hc), the latter being responsible for recognition of neuronal gangliosides and synaptic vesicle receptor, SV2C (Mahrhold, S. et al. (2006) & Dong, M. et al. (2006)).
  • the three main modules can be recognized as separate structural units in an X-ray model (adapted from Lacy et al. (1998), Fig. 24a).
  • the inventors first fused the SV2 -binding part (Hc) to synaptobrevin (Fig. 24b) and tested whether this fusion can deliver quantum dots (Q-dots) into neuronal endings.
  • the Hc-synaptobrevin fusion was able to form the SNARE complex with SNAP25 and a 52 amino acid syntaxin3 peptide labelled with biotin for binding to streptavidin-coated Q-dots.
  • the targeting part of BoNT/ A is still capable of recognizing its synaptic receptor and can deliver a large cargo following recombinant fusion with a SNARE tag.
  • the inventors prepared a fusion of the enzymatic part, translocating part and SNAP25 (Fig. 25a).
  • a thrombin cleavage instead of the native trypsin-sensitive site
  • Lc enzymatic
  • HN translocating parts
  • the fluorescent molecule colocalised to a significant degree with the vesicular marker synaptophysin indicating its binding to the native target of the
  • Fig. 27c shows that LcHN- SNARE-Hc paralysed the diaphragm muscle at subnanomolar concentrations (190 pM) within 72 min. No paralysis was observed in the absence of the linking syntaxin peptide (data not shown).
  • BoNT/A commonly known as BOTOX
  • the efficiency of the LcHN-SNARE-Hc in blocking neuromuscular junctions was less than the native BoNT/A (Mahrhold, S. et al. (2006)), this can be explained by either reduced ability of the extended toxin to reach distant active zones within long neuromuscular junctions or due to a large volume of the presynaptic ending at the diaphragm muscle leading to a compromised efficiency.
  • SNARE- tagged Hc part it is also possible to utilize the SNARE- tagged Hc part to deliver imaging agents and future therapeutics by tagging them with SNARE counterparts (Binz, T et al. (2009)). Further, it is possible to oligomerise Hc part for eliciting a stronger immune response when producing anti-botulinum serum (Webb, R. P. et al. (2007)).
  • the SNARE tagging of the LcHN part will also allow an easy- retargeting of the active portion of BoNT/A to specific neuroendocrine cells (Dolly, J. O. et al. (2009)). Here one can target neuropeptide or growth factor receptors by making corresponding SNARE-tagged ligands.
  • Such SNARE tagging can allow a convenient combinatorial mixing of various functional units with the aim of finding the most beneficial combination(s) to silence specific subsets of neurons (Foster, K. A. (2009)).
  • LcHN-SNAP25 The plasmid for expression of LcHN-SNAP25 was generated as follows: cDNA of BoNT/A Lc (amino acids 1-449) was amplified by PCR and inserted into Smal and EcoRI restrictions sites in the pGEX-KG vector (Guan, K. L. et al. (1991)). The codon optimised cDNA of BoNT/A translocation domain HN (amino acids 450-872, from ATG Biosynthetics, Germany) was inserted at the 3' end of light chain.
  • the thrombin cleavage site (amino acids LVPRGS (SEQ ID NO. 16)) was inserted between the light chain and the translocation domain of BoNT/A.
  • the cDNA of rat SNAP25B (aa 1-206) was inserted at the 3' end of HN.
  • the plasmid allowing expression of Hc-Syb was generated as follows: cDNA of rat synaptobrevin (amino acids 25-84) was amplified by PCR and inserted into pGEX-KG vector between BamHI and EcoRI sites.
  • the cDNA of the BoNT/A heavy chain (amino acids 876-1296) was amplified by PCR and inserted at the 3' end of synaptobrevin.
  • a peptide of the syntaxin3 SNARE motif (amino acids 200-250) was synthesized chemically with either biotin or fluorescein (Peptide Synthetics, UK). Proteins fused to GST were purified on glutathione Sepharose beads (GE Healhcare, USA) and eluted from beads in 20 mM Hepes, pH 7.3, 100 mM NaCl using thrombin. The supramolecular complexes were assembled by mixing the SNARE-tagged proteins with the syntaxin peptide for 1 hr at 22 0 C.
  • Mouse anti-synaptophysin antibody (clone 7.2) was from Synaptic Systems, and mouse anti-SNAP25 antibody (clone SMI81) was from Sternberger Monoclonals. Streptavidin- conjugated Q-dots 525 were from Invitrogen. Primary cultures of hippocampal neurons were prepared as described (Darios, F. et al. (2009)) and used after 7-10 days in vitro. Neurons were exposed to SNARE-tagged, or native toxin, for 2 hours, fixed with 4% PFA and then immunostained with anti-synaptophysin antibody.
  • neurons were incubated for 20 hours with assembled toxin or native BoNT/A, lysed in 60 mM Tris, pH 6.8, 2 mM MgCL 2 , 2% SDS, benzonase (Novagen, 250 U/ml) and then SNAP25 cleavage was analysed by immunobloting using an anti-SNAP25 antibody.
  • the phrenic nerve was continuously stimulated at 5-25 niA with a frequency of 1 Hz, 0.1 ms pulse duration. Isometric contractions were transformed using a force transducer and recorded with VitroDat Online software (FMI GmbH). The time required to decrease the amplitude to 50 % of the starting value (paralytic half- time) was determined. Additional Information
  • Botulinum neurotoxins are the most potent toxins designed by nature. These toxins are produced by Clostridium bacteria to cause long-lasting paralysis and death. Over the last 30 years, some members of the botulinum family, e.g. botulinum neurotoxin type A (BoNT/ A) also known as BOTOX, have been successfully exploited for medicinal and cosmetic purposes. These toxins silence neuromuscular junctions and also can block neurotransmitter release from many types of neurons. Practically every part of the human body, with the exception of the brain, can be treated by BOTOX. Since the paralysis of neuromuscular junctions is reversible, the sustained relaxation of muscles requires repeat injections every three to four months.
  • BoNT/ A botulinum neurotoxin type A
  • BoNT/A can block innervation of not only striated muscles but also of smooth muscles. Furthermore, the cholinergic junctions of the autonomous nervous system that control sweating, salivation and other types of secretion are as sensitive to BOTOX as are the neuromuscular junctions. Therefore, BOTOX-based treatments have recently expanded to include a dazzling array of nearly a hundred conditions from dystonias to gastrointestinal and urinary disorders.
  • BoNT/A has the longest paralysing effect among the seven immunologically distinct serotypes of BoNTs (A-G), thus underpinning the usefulness of specifically BoNT/A in the treatment of neurological disorders.
  • All BoNTs are synthesised by the bacteria as single polypeptide chains with a molecular mass of 150 kDa. Following bacterial death and lysis, the toxins are 'nicked' by bacterial proteases to yield the 50 kDa light and the 100 kDa heavy chains that are kept together by a disulphide bond. The two chains, still linked through the disulphide bond, traverse the intestinal epithelial cells by transcytosis, enter the bloodstream and eventually bind to peripheral cholinergic nerve terminals.
  • BoNTs The extreme toxicity of BoNTs indicates that the peripheral nerve endings carry molecules that can serve as BoNTs' high-affinity receptors. Indeed, several synaptic vesicle proteins have been shown to act as receptors for BoNTs. While the heavy chains are responsible for BoNTs' binding to nerve terminals, the light chains are potent endopeptidases that attack the vesicle fusion machinery and therefore have to get inside the nerve terminal. BoNTs accomplish this task by hijacking the vesicle endocytosis route. As the pH of the recycling vesicle's interior drops, the BoNTs undergo major conformational changes.
  • translocating part (known as FIN) of the heavy chains to form putative channels across the vesicular membrane through which the partially unfolded light chains slip into the cytosol.
  • FIN translocating part
  • BoNT light chains are potent endopeptidases that attack a number of isoforms of the three SNARE proteins that mediate vesicle fusion and therefore neurotransmitter release. It is now known that BoNT/A and BoNT/E proteolyse
  • BoNTs B, D, F and G cleave VAMP on the synaptic vesicles.
  • SNAP-25 shortened by only nine amino acids by BoNT/A retains its ability to interact with the plasma membrane syntaxin and vesicular synaptobrevin but cannot mediate the normal vesicle fusion process.
  • BoNTs botulinum neurotoxins
  • BoNTs can stop the neurotransmitter release of not only acetylcholine but also glutamate, glycine, noradrenaline, dopamine, serotonin, ATP and various neuropeptides (Ashton et al. (1988), Capogna, M. et al. (1997), Sanchez-Prieto, J. et al. (1987), Verderio, C.
  • BoNTs are naturally delivered by their partner heavy chains, but alternative means of delivery, such as liposomes or recombinant fusion constructs, are also effective (de Paiva, A. et al. (1990), Chaddock, J. A. et al. (2004), and Duggan, MJ. et al. (2002)). Recombinant chimeras of lectins with the BoNT/A light chain recently allowed delivery of the latter into nociceptive afferents or dorsal root ganglia (Chaddock, J.A. et al. (2004)).
  • the delivery efficiency can be easily tracked if the light chain is fused to a GFP fluorescent tag, allowing marking of the silenced cells.
  • the ability of the heavy chains of BoNTs to target synapses and transport their light chains into the nerve terminal offers another tool that can be utilised in neurobiology (Goodnough, M.C. et al. (2002) and Bade, S. et al. (2004)). Delivery of various molecules, especially enzymes, using BoNT heavy chains may be feasible for manipulation of synapse physiology. Indeed, it has recently been demonstrated that BoNT/D can deliver recombinantly attached enzymes into the nerve terminals (Bade, S. et al. (2004)).
  • the inventors have shown that it is possible to obtain a functional botulinum neurotoxin by recombining the toxin from two parts:
  • Receptor-binding part of the heavy chain (HC part) which carries on its N-terminus a SNARE tag (syntaxin, SNAP- 25 or synaptobrevin).
  • SNARE tags allow irreversible linking of functional units.
  • LCHN and HC can be produced separately in a protein-producing bacterial strain without health risks. Each part can be purified in a safe way. When the two parts are mixed they produce within 1 hour an active neurotoxin which can cleave its molecular target SNAP-25 in exposed neurons and also block neurotransmitter release from nerve endings. Since the LCHN part with a SNARE tag is functional (i.e. SNAP-25 neuronal cleavage and a blockade of neurotransmitter release is observed), it is possible to direct this active part to specific neurons or endocrine cells by adding a ligand with a SNARE tag for irreversible assembly of LCHN/ligand moiety.
  • somatostatin peptide linked to a SNARE tag Binding of the ligand to the intended cells can result in the transport of LCHN into the cell with subsequent release of the light chain and therefore SNAP-25 damage with subsequent halt in neurotransmitter or hormone release.
  • the HC part with a SNARE tag is functional (i.e. observation of a blockade of neurotransmitter release after attachment of LCHN/SNARE tagged), it is possible to use the SNARE tagged HC part for delivery of other enzymatic or imaging moieties into neurons. It is also possible to use other receptor-binding compounds (e.g. somatostatin neuropeptide) with a SNARE tag to deliver drugs, imaging reagents, etc. into specific cells that carry necessary receptors.
  • receptor-binding compounds e.g. somatostatin neuropeptide
  • Proteins were eluted in 20 mM Hepes, pH 7.3 , 100 mM NaCl from beads using thrombin.
  • BoNT/A Hc 876-1296
  • 0.8% octylglucoside was present in the elution buffer.
  • LcHN-Syb BoNT/A Lc(I -449) Thrombin HN(449-872)-Syb2 (1-96; WWK-AAA) - SEQ ID NO. 20
  • Syx3 peptide (45aa, 52 aa-FITC)
  • the inventors mixed for 1 hr the active part fused to one SNARE protein (LcHN-Syx, LcHN SNAP25 or LcHN-Syb) with the receptor binding part containing a second SNARE protein.
  • the assembly was locked by the addition of the third SNARE partner. Examples of combinations are given in the table:
  • EIIKLENSIRELHDMFMDMAMLVESQGEMIDRIEYNVEHAVDYVERAVSDTKKA (SEQ ID NO. 32) The following synthetic syntaxin peptides were tested:
  • Bio-NSIRELHDMFMDMAMLVESQGEMIDRIEYNVEHAVDYVEC (39 amino acids).
  • SNARE motifs can be employed for the complexing system.
  • Examples of stable, SDS- resistant complexes and their melting temperatures (Tm) are provided for SNARE complexes made of recombinant syntaxins 1 and 3, SNAP23 and SNAP25, and VAMPs 2, 4, 5, 7 and 8, as visualised in the SDS gels shown in Figure 36.
  • the complexing system affords uniting of 3 separate shortened polypeptide SNARE motifs.
  • VAMP2 Recombinant synaptobrevin fused to glutathione-S-transferase can be united with 40 and 45 amino acid syntaxinl and SNAP25 peptides.
  • SNAP25 peptides are designated as helix 1 (S25H1) and helix 2 (S25H2).
  • Syx 1 45 aa SEQ ID NO. 46;
  • S25H1 45 aa SEQ ID NO. 48;
  • S25H1 40 aa SEQ ID NO. 49;
  • S25H2 45 aa SEQ ID NO. 50;
  • S25H2 40 aa SEQ ID NO. 51.
  • Recombinant S25H2 protein can be united with 40 and 45 amino acid syntaxinl, VAMP2 and S25H1 peptides.
  • S25H1 45 aa SEQ ID NO. 48;
  • S25H1 40 aa SEQ ID NO. 49;
  • Syxl 40 aa SEQ ID NO. 47;
  • Syb2 45 aa SEQ ID NO. 52;
  • Syb2 40 aa SEQ ID NO. 53.
  • the results are shown in Figure 38 in which the lanes marked with + contain samples which were boiled in SDS and the lanes marked with - contain samples which were not boiled in SDS.
  • Recombinant S25H1 protein can be united with 40 and 45 amino acid syntaxinl, VAMP2 and S25H2 peptides.
  • S25H2 45 aa SEQ ID NO. 50;
  • S25H2 40 aa SEQ ID NO. 51;
  • Syxl 45 aa SEQ ID NO. 46;
  • Syxl 40 aa SEQ ID NO. 47;
  • Syb2 45 aa SEQ ID NO. 52;
  • Syntaxintag-SubstanceP (SEQ ID NO. 56)
  • lane 1 and 2 Brevintag-SubstanceP was mixed with Syntaxintag-somatostatin in the presence of SNAP25.
  • the stable complex contains both substanceP and somatostatin (heterodimeric peptide).
  • Lane 3 and 4 Brevintag-somatostatin was mixed with Syntaxintag-somatostatin in the presence of SNAP25.
  • the stable complex contains two somatostatins (homodimeric peptide). Note, lanes 1 and 3 show the stable complexes obtained using tagged neuropeptides.
  • Example 11 shows the stable complexes obtained using tagged neuropeptides.
  • Neuropeptides can be united with other functional groups, e.g. botulinum neurotoxin parts, in different orientations which could affect binding to cell surface receptors and translocation of peptides.
  • functional groups e.g. botulinum neurotoxin parts
  • Lanes 1 and 2 syntaxin-AVP was incubated with LcHn-brevin in the presence of SNAP-25 for 60 min.
  • the stable complex contains LcHn-SNARE-AVP (AVP is on the C-terminal end of the SNARE linkers).
  • Lanes 3 and 4 AVP-syntaxin was incubated with LcHn-brevin in the presence of SNAP-25 for 60 min.
  • the stable complex contains LcHn-AVP-SNARE (AVP is on the N-terminal end of the SNARE linkers).
  • Binding of the peptides was observed in a pull-down experiment using GST-SNAP251inkerSynaptobrevin protein (trihelical construct) immobilized on glutathione-beads. Binding was for 30 min at 25 degrees C, followed by extensive washing in buffer A (20 mM HEPES, 100 mM NaCl). Protein and peptides were visualised on SDS-gels ( Figure 42). Biotinylated peptides bound to beads are seen at the bottom of the SDS-gel.
  • SNARE peptides can be chemically cross-linked to proteins when the proteins cannot be expressed recombinantly.
  • the peptides retain their ability to form the SNARE complex and the modified proteins retain their activity. Sequences used:
  • Figure 43 is an SDS-gel showing maleimide-based cross-linking.
  • the cross-linked syntaxin-HRP can bind to GST-trihelix (Snap25-brevin, S-B) which was immobilized on glutathione beads.
  • S-B GST-trihelix
  • Figure 44 shows adsorbance at 650 nm of the TMB substrate.
  • Figure 45 shows luminescence of luminal visualized on film. Note, control glutathione beads without GST-trihelix (S-B) show only background binding of syntaxin-HRP.
  • a 29 amino acid complexin 1 peptide can interact with SNARE assemblies. This peptide can be used for purification following its immobilization or as an additional carrier in SNARE-based assemblies.
  • Figure 46 is an SDS-gel showing pull down of the complexin peptide by the following proteins immobilized on Ni2+ beads.
  • lane E represents a product where one recombinant protein binds three synthetic peptides one of which is the complexin peptide.
  • SNARE assembly can be accomplished in the presence of blood serum. Certain applications will require de novo interaction of SNARE-based medicines following their injection into blood.
  • the 45 amino acid syntaxinl peptide with FITC fluorescent tag was tested for binding to GST-trihelical protein (SNAP-25 linked to synaptobrevin, SB protein) immobilised on glutathione beads in the presence of 100% calf serum. The results are shown in Figure 47. Note, the presence of the trihelical protein on beads results in pull-down of the syntaxin fluorescent peptide in the presence of serum. The vertical axis represents relative fluorescence units.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

L'invention porte sur un système complexant comprenant deux hélices polypeptidiques issues d'une protéine SNAP; une hélice polypeptidique issue de la syntaxine; une hélice polypeptidique issue de la synaptobrévine ou d'un homologue de celle-ci; de l'andone ou plusieurs fractions porteuses attachées aux hélices polypeptidiques, les quatre hélices polypeptidiques pouvant former un complexe SNARE stable. L'invention porte également sur un procédé de production du système complexant et sur l'utilisation du système complexant.
PCT/GB2010/051336 2009-08-12 2010-08-12 Système complexant WO2011018665A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2012524293A JP2013501771A (ja) 2009-08-12 2010-08-12 複合体形成系
AU2010283595A AU2010283595A1 (en) 2009-08-12 2010-08-12 Complexing system
EP10747066A EP2464662A1 (fr) 2009-08-12 2010-08-12 Système complexant
CA2770357A CA2770357A1 (fr) 2009-08-12 2010-08-12 Systeme complexant
CN2010800444464A CN102625812A (zh) 2009-08-12 2010-08-12 复合系统

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0914121A GB0914121D0 (en) 2009-08-12 2009-08-12 Complexing systems
GB0914121.9 2009-08-12
US31920410P 2010-03-30 2010-03-30
US61/319,204 2010-03-30

Publications (1)

Publication Number Publication Date
WO2011018665A1 true WO2011018665A1 (fr) 2011-02-17

Family

ID=45812299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/051336 WO2011018665A1 (fr) 2009-08-12 2010-08-12 Système complexant

Country Status (6)

Country Link
EP (1) EP2464662A1 (fr)
JP (1) JP2013501771A (fr)
CN (1) CN102625812A (fr)
AU (1) AU2010283595A1 (fr)
CA (1) CA2770357A1 (fr)
WO (1) WO2011018665A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9170252B2 (en) 2012-10-23 2015-10-27 Ipsen Bioinnovation Limited Assay for assessment of endosomal transport
WO2018109447A1 (fr) * 2016-12-12 2018-06-21 The University Of Sheffield Neurotoxines
WO2019126502A1 (fr) * 2017-12-20 2019-06-27 Allergan, Inc. Polypeptides du domaine de liaison cellulaire de toxine botulique et procédés d'utilisation pour le rajeunissement de la peau
WO2019162696A1 (fr) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Utilisation d'ultrasons pour guider l'injection de protéase non-cytotoxique
US10408837B2 (en) * 2013-12-09 2019-09-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide substrates recognizable by type E botulinum neurotoxin
WO2019224184A1 (fr) 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression de l'allodynie induite par le cancer des os
WO2020115490A1 (fr) 2018-12-05 2020-06-11 Ipsen Biopharm Limited Traitement de symptômes d'une lésion cérébrale traumatique
WO2024064112A3 (fr) * 2022-09-19 2024-05-02 The Rockefeller University Capture d'affinité et détermination directe de structures de protéines et d'autres matieres sur des billes superparamagnétiques par une analyse de microscopie cryo-électronique à particule unique

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119061113A (zh) * 2023-05-31 2024-12-03 妍诗美社(海南)医美健康科技有限公司 一种检测毒素活性的体系以及方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20090035822A1 (en) 2004-12-01 2009-02-05 Keith Foster Fusion Proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331101A (zh) * 2000-06-28 2002-01-16 上海博德基因开发有限公司 一种新的多肽——snare相关的高尔基gs27蛋白20.68和编码这种多肽的多核苷酸
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
CN101027047A (zh) * 2002-12-03 2007-08-29 Ucb公司 鉴定用于治疗癫痫发作、神经疾病、内分泌病和激素疾病的药剂的方法
CN100497626C (zh) * 2004-10-18 2009-06-10 国家海洋局第一海洋研究所 分离的25kd突触相关蛋白及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20090035822A1 (en) 2004-12-01 2009-02-05 Keith Foster Fusion Proteins

Non-Patent Citations (86)

* Cited by examiner, † Cited by third party
Title
AOKI, K.R.; GUYER, B., EUR J NEUROL 8 SUPPL, vol. 5, 2001, pages 21 - 29
ASHTON, A.C.; DOLLY, J.O., J NEUROCHEM, vol. 50, no. 6, 1988, pages 1808 - 1816
AVLETOV, B.; BAJOHRS, M.; BINZ, T., TRENDS NEUROSCI, vol. 28, 2005, pages 446 - 452
BADE, S. ET AL., JNEUROCHEM, vol. 91, no. 6, 2004, pages 1461 - 1472
BESTEIRO, BMC GENOMICS, vol. 7, 2006, pages 250
BHATTACHARYA, S.; STEWART, B.A.; NIEMEYER, B.A.; BURGESS, R.W.; MCCABE, B.D.; LIN, P.; BOULIANNE, G.; O'KANE, C.J.; SCHWARZ, T.L., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, 2002, pages 13867 - 13872
BINZ, T. ET AL., JBIOL CHEM, vol. 265, no. 16, 1990, pages 9153 - 9158
BINZ, T.; RUMMEL, A., J NEUROCHEM, vol. 109, no. 6, 2009, pages 1584
BLANES-MIRA C ET AL: "Identification of SNARE complex modulators that inhibit exocytosis from an alpha-helix-constrained combinatorial library", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB LNKD- DOI:10.1042/BJ20030509, vol. 375, no. 1, 1 October 2003 (2003-10-01), pages 159 - 166, XP002402317, ISSN: 0264-6021 *
BLASI, J. ET AL., NATURE, vol. 365, no. 6442, 1993, pages 160
BOWEN, M.E.; WENINGER, K.; ERNST, J.; CHU, S.; BRUNGER, A.T., BIOPHYSICAL JOURNAL, vol. 89, 2005, pages 690 - 702
BROSE NILS: "For better or for worse: complexins regulate SNARE function and vesicle fusion.", September 2008, TRAFFIC (COPENHAGEN, DENMARK) SEP 2008 LNKD- PUBMED:18445121, VOL. 9, NR. 9, PAGE(S) 1403 - 1413, ISSN: 1600-0854, XP002607021 *
CÁNAVES J M ET AL: "Assembly of a ternary complex by the predicted minimal coiled-coil-forming domains of syntaxin, SNAP-25, and synaptobrevin. A circular dichroism study.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 18 DEC 1998 LNKD- PUBMED:9852083, vol. 273, no. 51, 18 December 1998 (1998-12-18), pages 34214 - 34221, XP002607015, ISSN: 0021-9258 *
CAPOGNA, M. ET AL., J NEUROSCI, vol. 17, no. 19, 1997, pages 7190 - 7202
CHADDOCK, J.A. ET AL., MOV DISORD, vol. 19, no. 8, 2004, pages 42 - 47
CHAPMAN E R ET AL: "SNAP-25, a t-SNARE which binds to both syntaxin and synaptobrevin via domains that may form coiled coils.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 4 NOV 1994 LNKD- PUBMED:7961655, vol. 269, no. 44, 4 November 1994 (1994-11-04), pages 27427 - 27432, XP002607019, ISSN: 0021-9258 *
COSTANTIN, L. ET AL., JNEUROSCI, vol. 25, no. 8, 2005, pages 1943 - 1951
DARIOS, F. ET AL., NEURON, vol. 62, no. 5, 2009, pages 683
DAVLETOV, B.; BAJOHRS, M.; BINZ, T., TRENDS NEUROSCI, vol. 28, no. 8, 2005, pages 446
DE PAIVA, A.; DOLLY, J.O., FEBS LETT, vol. 277, no. 1-2, 1990, pages 171 - 174
DOLLY, J. O. ET AL., CURR OPIN PHARMACOL, vol. 9, no. 3, 2009, pages 326
DOLLY, O., HEADACHE 43 SUPPL 1, 2003, pages 16 - 24
DONG, M. ET AL., SCIENCE, vol. 312, no. 5773, 2006, pages 592
DUGGAN, M.J. ET AL., J BIOL CHEM, vol. 277, no. 38, 2002, pages 34846 - 34852
ELLENA JEFFREY F ET AL: "Dynamic structure of lipid-bound synaptobrevin suggests a nucleation-propagation mechanism for trans-SNARE complex formation.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1 DEC 2009 LNKD- PUBMED:19918058, vol. 106, no. 48, 1 December 2009 (2009-12-01), pages 20306 - 20311, XP002607020, ISSN: 1091-6490 *
ENGEL, J.; KAMMERER, R.A., MATRIX BIOL, vol. 19, 2000, pages 283 - 288
FASSHAUER, D.; ANTONIN, W.; MARGITTAI, M.; PABST, S.; JAHN, R., J BIOL CHEM, vol. 274, 1999, pages 15440 - 15446
FASSHAUER, D.; MARGITTAI, M., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, 2004, pages 7613 - 7621
FOSTER, K. A., TOXICON, vol. 54, no. 5, 2009, pages 587
GIL C ET AL: "Synaptic proteins and SNARE complexes are localized in lipid rafts from rat brain synaptosomes", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US LNKD- DOI:10.1016/J.BBRC.2005.01.111, vol. 329, no. 1, 1 April 2005 (2005-04-01), pages 117 - 124, XP004757006, ISSN: 0006-291X *
GOODNOUGH, M.C. ET AL., FEBS LETT, vol. 513, no. 2-3, 2002, pages 163 - 168
GUAN, K. L.; DIXON, J. E., ANAL BIOCHEM, vol. 192, no. 2, 1991, pages 262
HAO, J.C.; SALEM, N.; PENG, X.R.; KELLY, R.B.; BENNETT, M.K., J NEUROSCI, vol. 17, 1997, pages 1596 - 1603
HAYASHI, T. ET AL., EMBO J, vol. 13, no. 21, 1994, pages 5051
HU ET AL.: "Action of Complexin on SNARE Complex.", J BIOL. CHEM., vol. 277, 2002, pages 41652 - 41656
HU, K.; CARROLL, J.; FEDOROVICH, S.; RICKMAN, C.; SUKHODUB, A.; DAVLETOV, B., NATURE, vol. 415, 2002, pages 646 - 650
J NEUROL NEUROSURG PSYCHIATRY, vol. 75, pages 951 - 957
JAHN R; SCHELLER RH., NAT REV MOL CELL BIOL, vol. 7, no. 9, September 2006 (2006-09-01), pages 631 - 43
JAHN R; SCHELLER RH., NAT REV MOL CELL BIOL., vol. 7, no. 9, September 2006 (2006-09-01), pages 631 - 43
JAHN REINHARD ET AL: "SNAREs--engines for membrane fusion.", NATURE REVIEWS. MOLECULAR CELL BIOLOGY SEP 2006 LNKD- PUBMED:16912714, vol. 7, no. 9, September 2006 (2006-09-01), pages 631 - 643, XP009139991, ISSN: 1471-0072 *
JANKOVIC, J., J NEUROL NEUROSURG PSYCHIATRY, vol. 75, no. 7, 2004, pages 951 - 957
JOHNSON, E.A., ANNU REV MICROBIOL, vol. 53, 1999, pages 551 - 575
KAMMERER, R.A.; KOSTREWA, D.; PROGIAS, P.; HONNAPPA, S.; AVILA, D.; LUSTIG, A.; WINKLER, F.K.; PIETERS, J.; STEINMETZ, M.O., PROC NATL ACAD SCI USA, vol. 102, 2005, pages 13891 - 13896
KARLSSON; FALT, JOURNAL OF IMMUNOLOGICAL METHODS, vol. 200, no. 1-2, 1997, pages 121 - 133
KASAI; AKAGAWA, JOURNAL OF CELL SCIENCE, vol. 114, 2001, pages 3115 - 3124
KOHN, M., J PEPT SCI, vol. 15, 2009, pages 393 - 397
LAAGE ET AL., JBIOL CHEM., vol. 275, 2000, pages 17481 - 7
LACY, D. B. ET AL., NAT STRUCT BIOL, vol. 5, no. 10, 1998, pages 898
LAUER, J.M.; DALAL, S.; MARZ, K.E.; NONET, M.L.; HANSON, P.I., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 14823 - 14832
LEHN, J. M., CHEM SOC REV, vol. 36, no. 2, 2007, pages 151
LEISNER, C.; LOETH, N.; LAMBERTH, K.; JUSTESEN, S.; SYLVESTER-HVID, C.; SCHMIDT, E.G.; CLAESSON, M.; BUUS, S.; STRYHN, A., PLOS ONE, vol. 3, 2008, pages E1678
LUVISETTO, S. ET AL., BEHAV PHARMACOL, vol. 15, no. 3, 2004, pages 233 - 240
MAHRHOLD, S. ET AL., FEBS LETT, vol. 580, no. 8, 2006, pages 2011
MCMAHON, H. T. ET AL., J BIOL CHEM, vol. 267, no. 30, 1992, pages 21338
MONTECUCCO, C. ET AL., TOXICON, vol. 54, no. 5, 2009, pages 561
MONTECUCCO, C.; SCHIAVO, G., TRENDS BIOCHEM SCI, vol. 18, no. 9, 1993, pages 324 - 327
O'SHEA, E.K.; LUMB, K.J.; KIM, P.S., CURR BIOL, vol. 3, 1993, pages 658 - 667
PILLAI, R.; MARINELLI, E.R.; SWENSON, R.E., BIOPOLYMERS, vol. 84, 2006, pages 576 - 585
POBBATI, A.V.; STEIN, A.; FASSHAUER, D., SCIENCE, vol. 313, 2006, pages 673 - 676
RICKMAN C; MEUNIER FA; BINZ T; DAVLETOV B, J. BIOL. CHEM., vol. 279, no. 1, 2 January 2004 (2004-01-02), pages 644 - 51
RICKMAN COLIN ET AL: "High affinity interaction of syntaxin and SNAP-25 on the plasma membrane is abolished by botulinum toxin E.", 2 January 2004, THE JOURNAL OF BIOLOGICAL CHEMISTRY 2 JAN 2004 LNKD- PUBMED:14551199, VOL. 279, NR. 1, PAGE(S) 644 - 651, ISSN: 0021-9258, XP002607018 *
RICKMAN; DAVLETOV, CHEMISTRY AND BIOLOGY MAY, vol. 12, no. 5, 2005, pages 545 - 53
ROSSI G ET AL., JBIOL CHEM., vol. 272, 1997, pages 16610 - 7
RYADNOV, M.G.; WOOLFSON, D.N., NATURE MATERIALS, vol. 2, 2003, pages 329 - 332
SANCHEZ-PRIETO, J. ET AL., EUR JBIOCHEM, vol. 165, no. 3, 1987, pages 675 - 681
SCHERR, N.; HONNAPPA, S.; KUNZ, G.; MUELLER, P.; JAYACHANDRAN, R.; WINKLER, F.; PIETERS, J.; STEINMETZ, M.O., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, 2007, pages 12151 - 12156
SCHIAVO, G. ET AL., FEBS LETT, vol. 335, no. 1, 1993, pages 99
See also references of EP2464662A1 *
SIEBER ET AL., BIOPHYS J., vol. 90, no. 8, 2006, pages 2843 - 2851
SIMPSON, L.L., REV PHARMACOL TOXICOL44, 2004, pages 167 - 193
SORENSEN ET AL: "SNARE complexes prepare for membrane fusion", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 28, no. 9, 1 September 2005 (2005-09-01), pages 453 - 455, XP005038571, ISSN: 0166-2236 *
SORENSEN JAKOB B ET AL: "Sequential N- to C-terminal SNARE complex assembly drives priming and fusion of secretory vesicles.", THE EMBO JOURNAL 8 MAR 2006 LNKD- PUBMED:16498411, vol. 25, no. 5, 8 March 2006 (2006-03-08), pages 955 - 966, XP002607022, ISSN: 0261-4189 *
STEIN ALEXANDER ET AL: "Helical extension of the neuronal SNARE complex into the membrane.", NATURE 23 JUL 2009 LNKD- PUBMED:19571812, vol. 460, no. 7254, 23 July 2009 (2009-07-23) - 1 July 2009 (2009-07-01), e-pub 01.07.09, pages 525 - 528, XP007915182, ISSN: 1476-4687 *
SUTTON, R.B.; FASSHAUER, D.; JAHN, R.; BRUNGER, A.T., NATURE, vol. 395, 1998, pages 347 - 353
TANAKA, T.; KAMIYA, N.; NAGAMUNE, T., BIOCONJUG CHEM, vol. 15, 2004, pages 491 - 497
TERPE, K., APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 60, 2003, pages 523 - 533
TOMIZAKI, K.Y.; USUI, K.; MIHARA, H., CHEMBIOCHEM, vol. 6, 2005, pages 782 - 799
TWEEDLE, M.F., CONTRAST MEDIA & MOLECULAR IMAGING, vol. 1, 2006, pages 2 - 9
UHLEN, M., BIOTECHNIQUES, vol. 44, 2008, pages 649 - 654
VERDERIO, C. ET AL., NEURON, vol. 41, no. 4, 2004, pages 599 - 610
VITES OLGA ET AL: "Docking of liposomes to planar surfaces mediated by trans-SNARE complexes.", BIOPHYSICAL JOURNAL AUG 2008 LNKD- PUBMED:18424501, vol. 95, no. 3, 18 April 2009 (2009-04-18), pages 1295 - 1302, XP002607014, ISSN: 1542-0086 *
WEBB, R. P. ET AL., VACCINE, vol. 25, no. 21, 2007, pages 4273
WENINGER ET AL: "Accessory Proteins Stabilize the Acceptor Complex for Synaptobrevin, the 1:1 Syntaxin/SNAP-25 Complex", STRUCTURE, CURRENT BIOLOGY LTD., PHILADELPHIA, PA, US LNKD- DOI:10.1016/J.STR.2007.12.010, vol. 16, no. 2, 12 February 2008 (2008-02-12), pages 308 - 320, XP022475308, ISSN: 0969-2126 *
WIEDERHOLD KATRIN ET AL: "Is assembly of the SNARE complex enough to fuel membrane fusion?", THE JOURNAL OF BIOLOGICAL CHEMISTRY 8 MAY 2009 LNKD- PUBMED:19258315, vol. 284, no. 19, 8 May 2009 (2009-05-08), pages 13143 - 13152, XP002607017, ISSN: 0021-9258 *
YANG, B.; GONZALEZ, L., JR.; PREKERIS, R.; STEEGMAIER, M.; ADVANI, R.J.; SCHELLER, R.H., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 5649 - 5653
ZHANG, S., NAT BIOTECHNOL, vol. 21, 2003, pages 1171 - 1178

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9170252B2 (en) 2012-10-23 2015-10-27 Ipsen Bioinnovation Limited Assay for assessment of endosomal transport
US10408837B2 (en) * 2013-12-09 2019-09-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide substrates recognizable by type E botulinum neurotoxin
WO2018109447A1 (fr) * 2016-12-12 2018-06-21 The University Of Sheffield Neurotoxines
WO2019126502A1 (fr) * 2017-12-20 2019-06-27 Allergan, Inc. Polypeptides du domaine de liaison cellulaire de toxine botulique et procédés d'utilisation pour le rajeunissement de la peau
WO2019126542A1 (fr) * 2017-12-20 2019-06-27 Allergan, Inc. Polypeptides du domaine de liaison cellulaire de toxine botulique et procédés d'utilisation pour des traitements de troubles associés à la fibrose
CN112351991A (zh) * 2017-12-20 2021-02-09 阿勒根公司 肉毒杆菌毒素细胞结合结构域多肽及其用于治疗纤维化相关障碍的方法
US11149262B2 (en) 2017-12-20 2021-10-19 Alleergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
WO2019162696A1 (fr) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Utilisation d'ultrasons pour guider l'injection de protéase non-cytotoxique
WO2019224184A1 (fr) 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression de l'allodynie induite par le cancer des os
WO2020115490A1 (fr) 2018-12-05 2020-06-11 Ipsen Biopharm Limited Traitement de symptômes d'une lésion cérébrale traumatique
WO2024064112A3 (fr) * 2022-09-19 2024-05-02 The Rockefeller University Capture d'affinité et détermination directe de structures de protéines et d'autres matieres sur des billes superparamagnétiques par une analyse de microscopie cryo-électronique à particule unique

Also Published As

Publication number Publication date
CN102625812A (zh) 2012-08-01
CA2770357A1 (fr) 2011-02-17
AU2010283595A1 (en) 2012-02-23
EP2464662A1 (fr) 2012-06-20
JP2013501771A (ja) 2013-01-17

Similar Documents

Publication Publication Date Title
WO2011018665A1 (fr) Système complexant
US10527609B2 (en) Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
JP6883529B2 (ja) 融合タンパク質を合成するための方法および製品
Wu et al. An intrinsically disordered peptide-peptide stapler for highly efficient protein ligation both in vivo and in vitro
US5723584A (en) Biotinylation of proteins
Howarth et al. Imaging proteins in live mammalian cells with biotin ligase and monovalent streptavidin
US20090220455A1 (en) Pharmaceutical compositions comprising elp fusion proteins
JP2019506163A (ja) 例外的なスプライシング活性を有するスプリットインテイン
CN110177811B (zh) 用于蛋白质连接的方法及其用途
Reinhardt et al. Rapid covalent fluorescence labeling of membrane proteins on live cells via coiled-coil templated acyl transfer
CN109641941B (zh) 用于纯化和激活肉毒杆菌神经毒素的方法
US8759488B2 (en) High stability streptavidin mutant proteins
JP2003527561A (ja) 蛋白の部位特異的標識化方法およびそのための使用
Hong Lim et al. Biotin‐assisted folding of streptavidin on the yeast surface
JP2024513126A (ja) ループまたは末端でペプチドタグと相互作用するポリペプチドおよびその使用
US20110038892A1 (en) Complexing system
Demircioglu et al. Purification and structural analysis of SUN and KASH domain proteins
Ren et al. Genetically encoded mechano-sensors with versatile readouts and compact size
Sonoda et al. Identification and preparation of a novel chemokine receptor-binding domain in the cytoplasmic regulator FROUNT
HRP20040242A2 (en) Protein knobs
Tang Synthesis and Characterization of pH-Responsive Elastin-Like Polypeptides with Different Configurations
Luisi Identification of novel protein scaffolds for small molecules binding and for catalysis
Rogers Negative interference in systems of coupled kinesin: A study of self-assembling complexes with defined structure
BR112017026042B1 (pt) Proteína de fusão e seu método de produção, ligante de peptídeo, par de ligantes de peptídeo e uso dos mesmos, polipeptídeo recombinante ou sintético, molécula de ácido nucleico, vetor, célula hospedeira recombinante e kit

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080044446.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10747066

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010283595

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1070/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2770357

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012524293

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010283595

Country of ref document: AU

Date of ref document: 20100812

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010747066

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载